Pharmacological, Regulatory and Global Health Dimensions of Opioid Use

Balancing Access to Essential Analgesics and the Prevention of Opioid-Related Harm

Doktorarbeit / Dissertation , 2026 , 84 Seiten , Note: A-

Medizin - Pharmakologie, Arzneimittelwesen, Pharmazie

Opioid analgesics are among the most effective medicines for the treatment of moderate to severe pain, yet their global use is marked by profound and persistent inequities. While high-income countries have experienced widespread opioid overuse and related morbidity and mortality, low- and middle-income countries continue to face severe under-access to essential opioid medicines, resulting in the systematic undertreatment of pain. This dual crisis—referred to in this thesis as the global opioid paradox—raises critical questions at the intersection of pharmaceutical science, global health, and regulatory policy.
This doctoral thesis adopts an interdisciplinary approach to examine how the pharmacological properties of opioids interact with regulatory frameworks and health system structures to shape population-level outcomes. Drawing on evidence from pharmacodynamics and pharmacokinetics, epidemiological data, and international and national policy analysis, the thesis explores why opioids have produced radically different public health consequences across regions despite their shared biological mechanisms.
The analysis demonstrates that opioids’ potent μ-opioid receptor–mediated analgesic effects are intrinsically linked to risks such as tolerance, dependence, and respiratory depression, making them particularly sensitive to regulatory context. In high-income countries, permissive prescribing cultures, aggressive pharmaceutical marketing, and fragmented oversight amplified these risks, contributing to an unprecedented opioid crisis. In contrast, in many low- and middle-income countries, restrictive interpretations of international drug control treaties, limited regulatory capacity, and inadequate health system infrastructure have created structural barriers to access, leaving millions without adequate pain relief. Through a detailed examination of international drug control conventions, the role of the World Health Organization, the European Medicines Agency, and national implementation mechanisms, the thesis highlights how policy intent, interpretation, and capacity influence opioid availability and use. It further evaluates pharmacological and policy-based solutions, including safer opioid formulations, non opioid analgesic strategies, balanced regulatory frameworks, and harm reduction interventions. The central conclusion of this work is that opioids are neither inherently beneficial nor inherently harmful;

TABLE OF CONTENTS

Declaration of Authenticity

Copyright Statement

Preface

Acknowledgements

Terminology

Policy Brief

Abstract / Executive Summary

Chapter 1: Introduction
1.1 Background and context
1.2 Opioids at the intersection of pharmacology and global health
1.3 Rationale and relevance of the study
1.4 Research objectives and questions
1.5 Methodological approach
1.6 Structure of the thesis

Chapter 2: Pharmacology of Opioids
2.1 Introduction to opioid pharmacology
2.2 Opioid receptors and mechanisms of action
2.3 Pharmacodynamics of opioid analgesics
2.4 Pharmacokinetics of opioid analgesics
2.5 Interindividual variability and pharmacogenomics
2.6 Implications for safety and global health

Chapter 3: Global Burden of Pain and Opioid Consumption Patterns
3.1 Introduction
3.2 The global burden of pain
3.3 Measurement of opioid consumption
3.4 Patterns of opioid use in high-income countries
3.5 Under-consumption in low- and middle-income countries
3.6 The global opioid paradox
3.7 Implications for pharmaceutical science and policy

Chapter 4: The Opioid Crisis in High-Income Countries
4.1 Introduction
4.2 The United States opioid crisis
4.3 The European opioid landscape
4.4 Comparative analysis: United States vs Europe
4.5 Lessons for pharmaceutical science and policy

Chapter 5: Under-Access to Opioids in Low- and Middle-Income Countries
5.1 Introduction
5.2 Scope and magnitude of opioid under-access
5.3 Regulatory barriers
5.4 Health system constraints
5.5 Cultural and societal factors
5.6 Ethical and human rights considerations

Chapter 6: Regulatory and Policy Frameworks Governing Opioid Use
6.1 The architecture of international drug control
6.2 United Nations drug control system
6.2.1 The Single Convention on Narcotic Drugs (1961)
6.2.2 Role of the International Narcotics Control Board (INCB)
6.3 World Health Organization and normative guidance
6.3.1 WHO Model List of Essential Medicines
6.3.2 WHO guidelines on pain management
6.4 European regulatory framework
6.4.1 Role of the European Medicines Agency (EMA)
6.4.2 EU-level coordination and limitations
6.5 National implementation and policy variation
6.6 Regulatory tension: Access versus control

Chapter 7: Balancing Access and Control: Pharmacological and Policy Solutions
7.1 Introduction
7.2 Pharmacological solutions
7.2.1 Development of safer opioid molecules (Biased ligands)
7.2.2 Abuse-deterrent formulations (ADFs)
7.2.3 Non-opioid and adjunctive analgesics
7.3 Policy-based solutions
7.3.1 Balanced opioid policy frameworks
7.3.2 Regulatory reform in low- and middle-income countries
7.3.3 Harm reduction strategies in high-income countries
7.4 Integrating pharmacology and policy
7.5 Global health equity considerations
7.6 Future directions and research priorities

Chapter 8: Discussion and Synthesis
8.1 Integration of findings
8.2 Pharmacology as a driver of population-level outcomes
8.3 Global health inequities and the opioid paradox
8.4 Role of regulatory and policy frameworks
8.5 Ethical and human rights implications
8.6 Limitations of the study

Chapter 9: Conclusions and Recommendations
9.1 Summary of key findings
9.2 Overarching conclusion
9.3 Recommendations for policy and regulation
9.3.1 Rebalancing international drug control
9.3.2 Strengthening national regulatory capacity
9.3.3 Integrating pain management into Universal Health Coverage (UHC)
9.4 Recommendations for pharmaceutical research and practice
9.5 Recommendations for global health action

References

Appendices

Preface

Over the past four years, the development of this thesis has been a transformative process of intellectual and professional evolution. This work is the result of a rigorous journey marked by continuous refinement, critical re-evaluation, and a shifting conceptual framework. My insights have matured significantly throughout this period, shaped not only by an exhaustive review of academic literature but also by a heightened awareness of the socio-political dimensions of public health.

A pivotal moment in this research occurred with the release of the "Painkiller" series, which detailed the OxyContin crisis in the United States. This served as a catalyst for expanding the scope of my investigation, prompting a transition from a regional analysis of opioid misuse to a comprehensive global perspective.

This doctoral journey has profoundly shaped my identity as both a researcher and a clinician. I have emerged with a more nuanced understanding of the complexities inherent in pharmaceutical ethics and patient care.

Acknowledgements

I wish to express my deepest gratitude to my parents. Their unwavering belief in my capabilities, especially during the most challenging phases of this work, was my greatest source of strength.

I am also profoundly grateful to Dr. Ahmed Mrinal. His steadfast support, accessibility, and intellectual guidance provided the necessary spark for many of the breakthroughs found within these pages.

Finally, I am confident that this thesis offers a substantive and original contribution to pharmaceutical academia. It is my hope that this work serves as a foundation for future inquiry and a catalyst for my continued career in this vital field.

Terminology

Pharmacological and Clinical Jargon

• p-opioid Receptor (MOR): A G-protein-coupled receptor that is the primary site of action for opioid analgesics. It mediates both the desired therapeutic effects (pain relief) and the life-threatening side effects (respiratory depression).

• Biased Agonism (Functional Selectivity): A sophisticated pharmacological approach where a ligand selectively activates specific intracellular pathways. The thesis highlights this as a future strategy to decouple analgesia from respiratory depression.

• Respiratory Depression: The most critical adverse effect of opioids, characterized by a decrease in the drive to breathe, which is the primary cause of death in opioid overdoses.

• Hyperalgesia (Opioid-Induced): A paradoxical clinical state where a patient receiving opioids for pain becomes more sensitive to painful stimuli, complicating long-term pain management.

• Multimodal Analgesia: The clinical practice of combining different classes of analgesics (e.g., opioids, NSAIDs, and gabapentinoids) to provide superior pain relief with lower doses of opioids, thereby reducing side effects.

• Pharmacokinetics (PK): The study of drug absorption, distribution, metabolism, and excretion (ADME). The thesis emphasizes the "first-pass effect" which dictates why certain opioids, like morphine, have different potencies when administered orally versus intravenously.

• Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs. This includes "binding affinity" (how strongly the drug holds the receptor) and "intrinsic activity" (the drug's ability to trigger a response).

Regulatory & Policy Terminology

• The Global Opioid Paradox: The central thesis framework describing the coexistence of "over-medicalization" and misuse in high-income countries (HICs) with "under-medicalization" and untreated pain in low- and middle­income countries (LMICs).

• Single Convention on Narcotic Drugs (1961): The landmark international treaty that established the dual obligation of nations to ensure the availability of narcotics for medical/scientific use while preventing illicit trafficking.

• Opiophobia: A socio-cultural and clinical phenomenon where fear of addiction and legal repercussions leads healthcare providers and policymakers to restrict opioid access even for patients with legitimate, severe pain.

• International Narcotics Control Board (INCB): The independent monitoring body for the implementation of United Nations drug conventions, responsible for tracking global consumption and estimates of medical opioids.

• Defined Daily Doses (S-DDD): A technical unit of measurement (defined by the WHO) used to normalize consumption data, allowing the thesis to compare opioid use across different nations regardless of the specific drug or dose.

• Controlled Substances Act (CSA): Reference to national legal frameworks (specifically in the US context) that categorize drugs into "Schedules" based on their medical utility versus their potential for abuse.

Ethical & Global Health Terminology

• Palliative Care: An approach that improves the quality of life of patients and their families facing the problems associated with life-threatening illness, through the prevention and relief of suffering.

• Structural Violence: A concept applied in the thesis to describe how systemic barriers—such as restrictive laws and poverty—prevent individuals from accessing basic pain relief, resulting in unnecessary suffering.

• Essential Medicines List (EML): The WHO-curated list of medicines that satisfy the priority healthcare needs of a population. The thesis argues for the mandatory inclusion and availability of morphine within this framework globally.

• Harm Reduction: A public health philosophy and set of practical strategies aimed at reducing the negative consequences associated with drug use, such as supervised injection sites and naloxone distribution.

• Iatrogenic Addiction: Substance use disorder that is inadvertently caused by medical treatment (e.g., a patient becoming addicted after being prescribed opioids for chronic back pain).

• The Fifth Vital Sign: A historical medical movement that encouraged clinicians to treat "pain" with the same urgency as blood pressure or heart rate, which the thesis identifies as a key driver of the over-prescription crisis in the late 20th century.

Policy Brief

Addressing the Global Opioid Paradox

To: Global Health Policymakers and National Regulatory Authorities

From: Newport University CED, Department of Medicine and Pharmacy

Date: December 8, 2025

Subject: Balancing Access to Essential Analgesics and the Prevention of Opioid- Related Harm

Executive Summary

This brief addresses the "global opioid paradox," a phenomenon where high-income countries face morbidity and mortality from opioid overuse while low- and middle­income countries suffer from severe under-access to essential pain relief. The pharmacological properties of opioids, mediated through the $\mu$-opioid receptor, provide indispensable analgesia but also carry inherent risks of dependence and respiratory depression. Resolving this crisis requires integrated, evidence-based strategies that balance medical access with public health safeguards.

The Challenge: Regulatory and Clinical Dualism

Opioid impact is determined by how their pharmacological properties are mediated through policy and health systems.

• Overuse in High-Income Countries: Driven by permissive prescribing cultures, aggressive marketing, and fragmented oversight, resulting in high rates of opioid use disorder and overdose.

• Under-access in Low- and Middle-Income Countries: Caused by restrictive interpretations of international drug control treaties, weak supply chains, and inadequate training, leaving millions with untreated cancer and end-of-life pain.

Key Policy Recommendations

1. Rebalance Regulatory Frameworks

International and national bodies must satisfy the legal obligation to ensure opioid availability for medical purposes while preventing diversion.

• For Low- and Middle-Income Countries: Simplify licensing and procurement procedures and expand the pool of authorized prescribers beyond a small number of specialists.

• For High-Income Countries: Strengthen prescription drug monitoring programs (PDMPs) and prioritize rational prescribing over punitive measures.

2. Integrate Pain Management into Universal Health Coverage (UHC)

Pain relief is an essential component of the right to health and human dignity.

• Explicitly incorporate palliative care and essential opioids, such as oral morphine, into national UHC benefit packages.

• Ensure reimbursement policies support both opioid and non-opioid multimodal pain management options.

3. Invest in Health Workforce Education

Clinician fear and "opiophobia" remain primary barriers to rational use.

• Implement mandatory training on opioid pharmacology, risk assessment, and the management of adverse effects like respiratory depression.

• Launch public health campaigns to combat stigma and misconceptions regarding medical opioid use.

4. Align Pharmaceutical Innovation with Public Health

Research should prioritize formulations that enhance safety and suitability for diverse global settings.

• Encourage development of safer molecules, such as biased p-opioid receptor agonists and partial agonists like buprenorphine.

• Promote low-cost, scalable solutions for resource-limited settings, such as locally produced oral morphine programs.

Abstract / Executive Summary

Opioid analgesics are among the most effective medicines for the treatment of moderate to severe pain, yet their global use is marked by profound and persistent inequities. While high-income countries have experienced widespread opioid overuse and related morbidity and mortality, low- and middle-income countries continue to face severe under-access to essential opioid medicines, resulting in the systematic undertreatment of pain. This dual crisis—referred to in this thesis as the global opioid paradox—raises critical questions at the intersection of pharmaceutical science, global health, and regulatory policy.

This doctoral thesis adopts an interdisciplinary approach to examine how the pharmacological properties of opioids interact with regulatory frameworks and health system structures to shape population-level outcomes. Drawing on evidence from pharmacodynamics and pharmacokinetics, epidemiological data, and international and national policy analysis, the thesis explores why opioids have produced radically different public health consequences across regions despite their shared biological mechanisms.

The analysis demonstrates that opioids’ potent p-opioid receptor-mediated analgesic effects are intrinsically linked to risks such as tolerance, dependence, and respiratory depression, making them particularly sensitive to regulatory context. In high-income countries, permissive prescribing cultures, aggressive pharmaceutical marketing, and fragmented oversight amplified these risks, contributing to an unprecedented opioid crisis. In contrast, in many low- and middle-income countries, restrictive interpretations of international drug control treaties, limited regulatory capacity, and inadequate health system infrastructure have created structural barriers to access, leaving millions without adequate pain relief.

Through a detailed examination of international drug control conventions, the role of the World Health Organization, the European Medicines Agency, and national implementation mechanisms, the thesis highlights how policy intent, interpretation, and capacity influence opioid availability and use. It further evaluates pharmacological and policy-based solutions, including safer opioid formulations, non­opioid analgesic strategies, balanced regulatory frameworks, and harm reduction interventions.

The central conclusion of this work is that opioids are neither inherently beneficial nor inherently harmful; their impact depends on how pharmacological properties are mediated through policy and health systems. Resolving the global opioid paradox requires integrated, evidence-based strategies that balance access and control, prioritize equity, and align pharmaceutical innovation with public health goals. By bridging pharmaceutical sciences with global health and regulatory analysis, this thesis aims to contribute to more humane, effective, and equitable opioid policy worldwide.

Chapter 1 - Introduction

1.1 Background and context

Pain is one of the most prevalent and debilitating health conditions worldwide. According to the World Health Organization, millions of people suffer from acute and chronic pain every year, arising from cancer, trauma, surgery, infectious diseases, and non-communicable conditions[1]. Effective pain management is therefore a cornerstone of modern medicine and an essential component of quality health care[2]. Among the pharmacological options available, opioid analgesics remain the most potent and indispensable medicines for the treatment of moderate to severe pain[3].

Opioids such as morphine, fentanyl, oxycodone, and methadone have been included on the WHO Model List of Essential Medicines for decades, reflecting their critical role in anesthesia, postoperative care, trauma medicine, and palliative care[4]. Their pharmacological efficacy is primarily mediated through activation of opioid receptors—most notably the p-opioid receptor—resulting in profound analgesia[5]. However, these same pharmacodynamic properties also underlie serious adverse effects, including respiratory depression, tolerance, physical dependence, and addiction[6].

Over the past three decades, opioid analgesics have become the subject of intense global scrutiny. In several high-income countries, most notably the United States and parts of Europe, the widespread prescribing of opioid medicines has contributed to what is commonly referred to as the “opioid crisis[7].” This phenomenon is characterized by high rates of opioid misuse, opioid use disorder, overdose, and opioid-related mortality[8]. In the United States alone, opioid overdoses have resulted in hundreds of thousands of deaths since the late 1990s, transforming a pharmacological tool intended for healing into a major public health emergency[9].

In stark contrast, the majority of low- and middle-income countries (LMICs) face a fundamentally different, yet equally severe, problem: a dramatic lack of access to opioid analgesics. Despite bearing a substantial share of the global burden of pain— particularly cancer-related and end-of-life pain—many LMICs consume only a fraction of the world’s legally produced morphine[10]. Patients in these settings often die in severe, untreated pain due to restrictive regulations, inadequate supply chains, lack of trained prescribers[11], and persistent fears of addiction and diversion[12].

This global imbalance reveals a profound paradox in opioid pharmacotherapy: while some regions suffer from excess availability and misuse, others experience extreme under-availability and therapeutic neglect[13]. Understanding and addressing this paradox requires an integrated approach that goes beyond clinical pharmacology alone and incorporates regulatory frameworks, health system capacity, and global health governance[1415].

1.2 Opioids at the intersection of pharmacology and global health

From a pharmaceutical sciences perspective, opioids represent a class of drugs with well-characterized mechanisms of action, pharmacokinetic profiles, and risk-benefit trade-offs[16]. Extensive research has elucidated receptor binding affinities, metabolic pathways, genetic variability in opioid response, and the molecular basis of tolerance and dependence[17]. These pharmacological insights have driven the development of novel formulations, including extended-release preparations and abuse-deterrent technologies[18].

However, pharmacology does not operate in a vacuum. The real-world impact of opioid medicines is heavily shaped by regulatory decisions, prescribing practices, and socio-political contexts[19]. International drug control treaties, particularly the Single Convention on Narcotic Drugs of 1961, have profoundly influenced national opioid policies by prioritizing control and prevention of diversion[20]. While these treaties explicitly recognize the medical necessity of opioids, their implementation has often favored restrictive interpretations, especially in resource-limited settings[21].

Global health, as a discipline, emphasizes equity, population-level outcomes, and the social determinants of health. When applied to opioid pharmacotherapy, a global health lens reveals deep inequities in access to essential medicines, ethical tensions between control and care, and the unintended consequences of policy decisions[22]. The opioid crisis in high-income countries and the pain crisis in LMICs are not

separate phenomena, but interconnected outcomes of how opioid pharmacology is regulated and operationalized worldwide[2324].

Bridging pharmaceutical sciences and global health allows for a more comprehensive understanding of opioids as both life-saving medicines and potential agents of harm[25]. Such an interdisciplinary approach is essential to designing policies and interventions that ensure adequate access to pain relief while minimizing the risk of misuse and addiction[2627].

1.3 Rationale and relevance of the study

Despite extensive literature on opioid pharmacology and growing research on opioid- related public health harms, there remains a gap in integrative analyses that explicitly link pharmacological characteristics with global patterns of access, misuse, and regulation. Many studies focus either on molecular mechanisms and clinical outcomes or on policy and epidemiology, without sufficiently examining how these domains interact.

This PhD thesis seeks to address this gap by situating opioid pharmacology within a global health and regulatory context. By examining how the intrinsic properties of opioid drugs intersect with international treaties, national policies, and health system constraints, the thesis aims to provide a holistic understanding of the global opioid paradox.

The relevance of this research is multifold. From a pharmaceutical sciences standpoint, it highlights how drug properties influence and are influenced by regulatory environments. From a global health perspective, it contributes to ongoing debates on access to essential medicines, health equity, and ethical pain management. Finally, from a policy and regulatory science perspective, the findings may inform more balanced approaches to opioid control that protect public health without perpetuating unnecessary suffering.

1.4 Research objectives and questions

The primary objective of this thesis is to analyze the pharmacological, regulatory, and global health dimensions of opioid use in order to understand and address global inequities in access and harm.

The central research question guiding this work is:

How do the pharmacological characteristics of opioid analgesics interact with global regulatory frameworks and health system factors to shape disparities in opioid access, misuse, and opioid-related harm worldwide?

To answer this overarching question, the thesis addresses the following sub­questions:

1. What are the key pharmacodynamic and pharmacokinetic properties of commonly used opioid analgesics, and how do these properties contribute to both therapeutic efficacy and risk?

2. How is opioid consumption distributed globally, and what patterns of overuse and underuse can be observed across different income settings?

3. How have international drug control treaties and national regulatory frameworks influenced opioid availability and prescribing practices?

4. What lessons can be drawn from case studies in high-income countries experiencing opioid overuse and in LMICs facing severe under-access?

5. Which pharmacological innovations and policy interventions show promise in achieving a more balanced and equitable approach to opioid use?

1.5 Methodological approach

This thesis adopts a qualitative and analytical research design grounded in pharmaceutical sciences and global health. The study is based primarily on an extensive review and synthesis of peer-reviewed scientific literature, policy documents, and reports from international organizations such as the World Health Organization, the International Narcotics Control Board, and the United Nations Office on Drugs and Crime.

In addition, comparative case studies are used to illustrate divergent opioid trajectories in selected countries. These case studies draw on epidemiological data, regulatory analyses, and secondary data sources to contextualize pharmacological findings within real-world settings.

1.6 Structure of the thesis

Following this introductory chapter, Chapter 2 provides a detailed overview of the pharmacology of opioid analgesics, focusing on receptor mechanisms, pharmacokinetics, and adverse effects. Chapter 3 examines the global burden of pain and patterns of opioid consumption worldwide. Chapter 4 analyzes the opioid crisis in high-income countries, while Chapter 5 focuses on under-access to opioids in LMICs. Chapter 6 explores international and national regulatory frameworks governing opioid use. Chapter 7 discusses pharmacological and policy-based solutions to balance access and control. Finally, Chapters 8 and 9 present the discussion, conclusions, and recommendations.

Together, these chapters aim to contribute to a more integrated and ethically grounded understanding of opioid pharmacotherapy in a global context.

Chapter 2 - Pharmacology of Opioids

2.1 Introduction to opioid pharmacology

Opioid analgesics constitute a pharmacologically distinct and clinically indispensable class of drugs used primarily for the management of moderate to severe pain[28]. Their therapeutic utility is rooted in their ability to modulate nociceptive signaling at multiple levels of the central and peripheral nervous system[29]. At the same time, opioids are associated with a narrow therapeutic index and a range of serious adverse effects, making a thorough understanding of their pharmacology essential for both clinical practice and policy decision-making[30].

This chapter provides a comprehensive overview of opioid pharmacology, beginning at the receptor and molecular level and extending through pharmacokinetics (PK) and pharmacodynamics (PD)[31]. Emphasis is placed on how intrinsic drug properties contribute to both analgesic efficacy and risk, thereby laying the scientific foundation for later discussions on misuse, regulation, and global health implications[323334].

2.2 Opioid receptors and mechanisms of action

2.2.1 Opioid receptor families

The effects of opioid drugs are mediated through their interaction with a family of G protein-coupled receptors (GPCRs), collectively referred to as opioid receptors[35].

Three primary receptor subtypes have been identified and extensively characterized: the p (mu), k (kappa), and 6 (delta) opioid receptors[36]. A fourth receptor, the nociceptin/orphanin FQ receptor (NOP), is structurally related but functionally distinct and is sometimes considered separately[37].

The p-opioid receptor (MOR) is the principal mediator of clinically relevant analgesia[38]. Activation of MOR produces potent pain relief but is also responsible for many adverse effects, including respiratory depression, euphoria, physical dependence, and addiction[39]. k-opioid receptors (KOR) contribute to spinal analgesia and modulate visceral pain but are associated with dysphoria and psychotomimetic effects[40]. 6-opioid receptors (DOR) play a role in analgesia and mood regulation and have been implicated in the modulation of emotional responses to pain[41].

The distribution of opioid receptors throughout the central nervous system—including the brainstem, thalamus, limbic system, and spinal cord dorsal horn—explains the

broad range of opioid effects on pain perception, respiration, mood, and reward pathways[424344].

2.2.2 Signal transduction pathways

Upon binding of an opioid agonist, opioid receptors undergo conformational changes that lead to coupling with inhibitory G proteins (Gi/Go)[45]. This interaction results in inhibition of adenylate cyclase, reduced cyclic adenosine monophosphate (cAMP) production, and subsequent downstream effects[46]. Additionally, opioid receptor activation promotes the opening of potassium channels and inhibition of voltage­gated calcium channels, leading to neuronal hyperpolarization and reduced neurotransmitter release[47].

These cellular mechanisms collectively suppress nociceptive transmission at both presynaptic and postsynaptic sites[48]. Importantly, chronic opioid exposure induces compensatory changes in these signaling pathways, including upregulation of adenylate cyclase activity, which contributes to the development of tolerance and dependence[49].

2.2.3 Biased agonism and emerging concepts

Recent advances in opioid pharmacology have highlighted the concept of biased agonism, whereby different opioid ligands preferentially activate specific intracellular signaling pathways[50]. For example, MOR activation can signal through both G protein-dependent pathways and p-arrestin-mediated pathways[51]. Evidence suggests that p-arrestin signaling is associated with adverse effects such as respiratory depression and constipation, whereas G protein-mediated signaling is more closely linked to analgesia[52].

This insight has driven the development of so-called biased opioid agonists aimed at maximizing analgesia while minimizing adverse outcomes[53]. Although promising, the clinical translation of biased agonism remains an area of ongoing research and debate[54].

2.3 Pharmacodynamics of opioid analgesics

2.3.1 Analgesic effects

Opioid analgesia results from modulation of pain signaling at multiple levels, including peripheral nociceptors, the spinal cord, and supraspinal structures[55]. At the spinal

level, opioids inhibit the release of excitatory neurotransmitters such as substance P and glutamate from primary afferent neurons[56]. Supraspinally, opioids activate descending inhibitory pathways that further suppress nociceptive transmission[57].

The magnitude of analgesic effect varies among opioid agents depending on receptor affinity, intrinsic activity, and central nervous system penetration[58]. Strong opioids such as morphine, fentanyl, and oxycodone exhibit high MOR affinity and robust analgesic efficacy, whereas weak opioids like codeine rely partly on metabolic conversion to active metabolites[5960].

2.3.2 Tolerance, dependence, and addiction

Repeated opioid administration leads to tolerance, defined as a reduction in drug effect over time requiring increasing doses to achieve the same level of analgesia[61]. Tolerance is mediated by receptor desensitization, downregulation, and adaptive cellular responses within opioid signaling pathways[6263].

Physical dependence arises from neuroadaptive changes that manifest as withdrawal symptoms upon abrupt cessation or antagonist administration[64]. These symptoms include agitation, pain hypersensitivity, gastrointestinal distress, and autonomic dysregulation[65]. Addiction, or opioid use disorder, is a distinct but related condition characterized by compulsive drug-seeking behavior and loss of control, driven largely by opioid effects on mesolimbic reward pathways[66].

2.3.3 Adverse pharmacodynamic effects

In addition to analgesia, opioids produce a range of dose-dependent adverse effects. Respiratory depression, resulting from MOR activation in the brainstem respiratory centers, represents the most serious and potentially fatal complication[67]. Other common adverse effects include sedation, nausea, vomiting, constipation, miosis, and endocrine dysfunction[6869].

The risk of these adverse effects is influenced by patient-specific factors[70], co­administration of other central nervous system depressants[71], and pharmacokinetic properties of the opioid used[72].

2.4 Pharmacokinetics of opioid analgesics

2.4.1 Absorption and routes of administration

Opioids can be administered via multiple routes, including oral, intravenous, transdermal, subcutaneous, and intrathecal delivery[73]. Oral bioavailability varies widely among opioids due to differences in gastrointestinal absorption and first-pass hepatic metabolism[74]. For example, morphine exhibits relatively low oral bioavailability, whereas oxycodone and methadone demonstrate higher and more predictable absorption[75].

Transdermal systems, such as fentanyl patches, provide sustained drug delivery but carry risks related to delayed onset and prolonged elimination, particularly in the context of overdose[76].

2.4.2 Distribution and blood-brain barrier penetration

Once absorbed, opioids distribute extensively throughout body tissues[77]. Their ability to cross the blood-brain barrier is largely determined by lipophilicity and plasma protein binding[78]. Highly lipophilic opioids such as fentanyl rapidly penetrate the central nervous system, resulting in rapid onset of action but also increased overdose risk[79].

Volume of distribution and tissue sequestration can significantly influence duration of action and accumulation, particularly with repeated dosing[80].

2.4.3 Metabolism and elimination

Most opioids undergo hepatic metabolism, primarily via cytochrome P450 enzymes and phase II conjugation pathways[81]. Morphine is metabolized mainly through glucuronidation to morphine-3-glucuronide and morphine-6-glucuronide, the latter possessing significant analgesic activity[82]. In contrast, opioids such as oxycodone and fentanyl are metabolized predominantly by CYP3A4, making them susceptible to drug-drug interactions[83].

Renal excretion represents the primary route of elimination for many opioid metabolites, rendering patients with renal impairment particularly vulnerable to drug accumulation and toxicity[84].

2.5 Interindividual variability and pharmacogenomics

Significant interindividual variability exists in opioid response, influenced by genetic, physiological, and environmental factors[85]. Polymorphisms in genes encoding opioid receptors, metabolic enzymes, and transporters can affect analgesic efficacy and risk of adverse effects[86]. For instance, CYP2D6 polymorphisms influence the conversion of codeine to morphine, leading to reduced efficacy in poor metabolizers and increased toxicity in ultra-rapid metabolizers[87].

Understanding pharmacogenomic variability holds promise for more personalized and safer opioid prescribing, though its integration into routine clinical practice remains limited[88].

2.6 Implications for safety and global health

The pharmacological properties of opioids that confer potent analgesia simultaneously create significant risks at both individual and population levels[89]. Rapid central nervous system penetration, high receptor efficacy, and complex metabolism contribute to overdose potential and variability in response[90]. When combined with weak regulatory oversight or, conversely, overly restrictive policies, these properties can lead to widespread harm or untreated pain[91].

From a global health perspective, pharmacokinetic and pharmacodynamic complexity poses particular challenges in low-resource settings, where monitoring, dose titration, and management of adverse effects may be limited[92]. These considerations underscore the need for regulatory and policy frameworks that are informed by pharmacological science and adapted to local health system capacities[93].

2.7 Conclusion

This chapter has outlined the fundamental pharmacology of opioid analgesics, from receptor-level mechanisms to pharmacokinetic behavior and sources of variability. By elucidating how opioids exert their therapeutic and adverse effects, this chapter provides the scientific foundation for subsequent analyses of opioid use, misuse, and regulation in a global context. The interplay between pharmacological properties and real-world application remains central to understanding the global opioid paradox addressed in this thesis.

Chapter 3 - Global Burden of Pain and Opioid Consumption Patterns

3.1 Introduction

Pain constitutes a major public health challenge worldwide and is a leading cause of disability, reduced quality of life, and healthcare utilization. Unlike many disease­specific conditions, pain cuts across virtually all clinical domains, including oncology, surgery, trauma, infectious diseases, and chronic non-communicable diseases. Despite advances in medical science, the global distribution of effective pain management remains profoundly unequal. This chapter examines the global burden of pain and analyzes patterns of opioid consumption across regions and income groups, highlighting the striking disparities that underpin the global opioid paradox.

3.2 The global burden of pain

3.2.1 Epidemiology of pain

Pain is one of the most commonly reported symptoms worldwide. Data from the Global Burden of Disease (GBD) studies indicate that conditions associated with chronic pain—such as low back pain, osteoarthritis, cancer, and neuropathic disorders—are among the leading contributors to years lived with disability (YLDs) globally[94]. Low back pain alone consistently ranks as the single largest cause of disability across all regions and income levels[95].

Acute pain related to surgery, trauma, and obstetric care also represents a substantial but less well-quantified burden, particularly in low- and middle-income countries (LMICs), where access to anesthesia and postoperative analgesia is often limited[96]. In these settings, untreated acute pain frequently transitions into chronic pain states, compounding long-term disability and economic loss[97].

3.2.2 Cancer-related and end-of-life pain

Cancer pain represents a critical subset of the global pain burden[98]. It is estimated that more than 60% of patients with advanced cancer experience moderate to severe pain requiring opioid therapy[99]. As cancer incidence rises globally—particularly in LMICs due to demographic transitions—the demand for effective opioid analgesia is expected to increase substantially[100].

End-of-life pain is especially prevalent in palliative care settings, where opioids are considered the standard of care[101]. However, access to palliative care services and essential opioid medicines remains severely constrained in many regions, resulting in widespread and preventable suffering[102].

3.2.3 Pain and socioeconomic determinants

The experience and management of pain are strongly influenced by socioeconomic factors. Poverty, limited healthcare infrastructure, inadequate workforce training, and cultural attitudes toward pain all shape access to diagnosis and treatment. In LMICs, pain is frequently under-recognized and undertreated, while in some high-income countries (HICs), aggressive pain management strategies have contributed to excessive opioid exposure.

3.3 Measurement of opioid consumption

3.3.1 Metrics and data sources

Global opioid consumption is commonly measured using standardized indicators such as defined daily doses (DDD) per capita or morphine milligram equivalents (MME)[103]. International organizations, including the International Narcotics Control Board (INCB), collect and publish data on the production, distribution, and consumption of controlled opioid medicines[104].

While these metrics allow for cross-country comparisons, they have important limitations[105]. Consumption data often reflect legal availability rather than actual clinical need, and they may not capture illicit opioid use or informal markets[106]. Nonetheless, these indicators provide valuable insight into broad patterns of access and inequality[107].

3.3.2 Global distribution of opioid consumption

Analyses of INCB data consistently demonstrate an extreme concentration of opioid consumption in a small number of high-income countries[108]. North America, Western Europe, and Australia account for the vast majority of the world’s legally consumed opioid analgesics, despite representing a minority of the global population[109].

In contrast, many LMICs consume negligible amounts of opioids on a per capita basis[110]. Some countries report consumption levels close to zero, even in the presence of substantial cancer burden and unmet palliative care needs[111]. This uneven distribution highlights a fundamental mismatch between global pain burden and opioid availability[112].

3.4 Patterns of opioid use in high-income countries

3.4.1 Expansion of opioid prescribing

In several HICs, particularly the United States, opioid prescribing increased dramatically from the late 1990s onward[113]. This expansion was driven by multiple factors, including changing perceptions of pain as the “fifth vital sign,” aggressive pharmaceutical marketing, and reassurances regarding the safety and low addiction potential of prescription opioids[114].

As prescribing rates rose, so did rates of opioid misuse, dependence, and overdose[115]. Prescription opioids initially accounted for a large share of opioid-related harms, later giving way to illicit opioids such as heroin and synthetic fentanyl as regulatory controls tightened[116].

3.4.2 Health and social consequences

The consequences of excessive opioid availability in HICs have been profound[117]. Opioid use disorder, overdose mortality, neonatal abstinence syndrome, and broader social disruptions have placed enormous strain on health systems and communities[118]. These outcomes underscore the risks associated with liberal opioid prescribing in the absence of adequate safeguards and monitoring[119].

3.5 Under-consumption of opioids in low- and middle-income countries

3.5.1 Structural barriers to access

In LMICs, opioid under-consumption is driven by a combination of regulatory, logistical, and educational barriers[120]. Strict narcotics regulations, complex licensing requirements, and fear of diversion often discourage procurement and prescribing[121]. Supply chain weaknesses further limit availability, particularly in rural and underserved areas[122].

Additionally, limited training in pain management and palliative care contributes to under-prescribing, even when opioids are legally available[123]. Misconceptions about addiction and respiratory depression persist among healthcare providers and policymakers[124].

3.5.2 Ethical and clinical implications

The failure to provide adequate pain relief in LMICs raises serious ethical concerns[125]. Untreated pain violates principles of human dignity and has been framed by some scholars as a form of structural violence[126]. From a clinical perspective, inadequate analgesia compromises patient outcomes, adherence to treatment, and quality of life[127].

3.6 The global opioid paradox

The juxtaposition of opioid overuse in HICs and severe underuse in LMICs constitutes what has been termed the global opioid paradox[128]. This paradox reflects not only differences in disease burden but also divergent regulatory responses, health system capacities, and interpretations of international drug control obligations[129].

Crucially, both extremes result in harm: excess leads to addiction and mortality, while scarcity results in untreated pain and suffering[130]. Addressing this paradox requires a balanced, evidence-based approach informed by pharmacology, epidemiology, and global health principles[131].

3.7 Implications for pharmaceutical science and policy

For pharmaceutical scientists, understanding global consumption patterns underscores the importance of developing opioid formulations and delivery systems that align with diverse health system contexts[132]. For policymakers, the data highlight the need for differentiated strategies that expand access where it is lacking while implementing safeguards where misuse is prevalent[133].

This chapter provides the epidemiological and contextual foundation for subsequent analyses of regulatory frameworks and policy responses, which are explored in the following chapters.

3.8 Conclusion

The global burden of pain is substantial and unevenly distributed, as is access to effective opioid analgesia. Patterns of opioid consumption reveal profound inequities that reflect broader structural and policy-driven factors. Recognizing and addressing these disparities is essential to achieving equitable pain management and resolving the global opioid paradox that lies at the heart of this thesis.

Chapter 4 - The Opioid Crisis in High-Income Countries: United States and European Perspectives

4.1 Introduction

While opioids remain essential medicines for the treatment of moderate to severe pain, their widespread availability and use in several high-income countries (HICs) has led to significant public health crises. The opioid crisis, most prominently observed in the United States but increasingly relevant in parts of Europe, illustrates the potential harms that arise when potent pharmacological agents are deployed without adequate regulatory oversight, clinical safeguards, and societal awareness. This chapter examines the origins, evolution, and consequences of the opioid crisis in HICs, with a primary focus on the United States and a comparative analysis of selected European contexts.

4.2 The United States opioid crisis

4.2.1 Historical development

The modern opioid crisis in the United States emerged in the late 1990s and early 2000s, following a marked shift in pain management paradigms[134]. Pain began to be framed as the “fifth vital sign,” prompting healthcare providers to prioritize aggressive pain control[135]. Concurrently, pharmaceutical companies marketed new opioid formulations—most notably extended-release oxycodone—as safe and effective for chronic non-cancer pain, often downplaying the risks of addiction and dependence[136].

These developments coincided with regulatory and institutional factors that facilitated high-volume opioid prescribing[137]. Professional guidelines, continuing medical education programs, and patient satisfaction metrics all contributed to a clinical environment in which opioid prescribing was normalized and incentivized[138].

4.2.2 Prescribing patterns and pharmaceutical influence

Opioid prescribing rates in the United States increased dramatically over a relatively short period[139]. By the early 2010s, the volume of opioid prescriptions reached levels far exceeding those observed in other countries[140]. Pharmaceutical marketing strategies, including targeted promotion to physicians and misleading claims regarding addiction risk, played a critical role in shaping prescribing behavior[141].

From a pharmacological perspective, the widespread use of high-dose, long-acting opioid formulations increased cumulative opioid exposure and heightened the risk of tolerance, dependence, and overdose[142]. The pharmacokinetic properties of these formulations—particularly delayed peak effects and prolonged elimination— contributed to inadvertent overdosing and accumulation[143].

4.2.3 Transition to illicit opioids

As awareness of opioid-related harms grew and prescribing practices became more restrictive, many individuals with opioid dependence transitioned from prescription opioids to illicit substances[144]. Heroin use increased markedly, followed by a surge in the availability of illicitly manufactured synthetic opioids, particularly fentanyl and its analogues[145].

Illicit fentanyl, characterized by extreme potency and unpredictable dosing, dramatically escalated overdose mortality. Its pharmacodynamic profile—high p- opioid receptor affinity and rapid central nervous system penetration—renders even small dosing errors potentially fatal[146]. This shift marked a new phase of the opioid crisis, dominated by synthetic opioids rather than prescription medicines[147].

4.2.4 Health, social, and economic consequences

The opioid crisis has had far-reaching consequences in the United States[148]. Opioid- related overdoses have resulted in hundreds of thousands of deaths, with significant impacts on life expectancy and population health indicators[149]. Beyond mortality, opioid use disorder has contributed to increased rates of infectious diseases, including HIV and hepatitis C, as well as substantial economic costs related to healthcare utilization, lost productivity, and criminal justice involvement[150].

4.3 The European opioid landscape

4.3.1 Opioid prescribing in Europe

Compared to the United States, most European countries have historically maintained more conservative opioid prescribing practices[151]. Stronger primary care systems, tighter regulatory controls, and less aggressive pharmaceutical marketing have limited the scale of opioid exposure in many European contexts[152].

Nevertheless, opioid prescribing has increased in several European countries over the past two decades, particularly for chronic non-cancer pain[153]. Variability exists across regions, with higher prescribing rates observed in countries such as the

United Kingdom, Germany, and the Nordic states, while Southern and Eastern European countries generally report lower consumption[154].

4.3.2 Emerging risks and trends

Although Europe has largely avoided a crisis of the magnitude seen in the United States, concerning trends have emerged[155]. Rising opioid-related hospitalizations, increasing use of strong opioids, and the growing presence of synthetic opioids in illicit drug markets have raised alarms among public health authorities[156].

The pharmacological risks associated with opioid therapy—tolerance, dependence, and overdose—are universal, and European health systems are not immune to these dynamics[157]. Differences in regulatory frameworks and harm reduction approaches, however, have influenced outcomes[158].

4.3.3 Harm reduction and regulatory responses

European countries have generally adopted more comprehensive harm reduction strategies, including widespread access to opioid substitution therapy (OST), needle exchange programs, and supervised consumption facilities in some jurisdictions[159]. These interventions have mitigated some of the most severe consequences of opioid misuse[160].

Regulatory responses in Europe have also emphasized cautious prescribing, guideline development, and monitoring systems[161]. These measures have helped contain opioid-related harms but require continuous adaptation in the face of evolving drug markets[162].

4.4 Comparative analysis: United States vs Europe

A comparison between the United States and Europe reveals important differences in how opioid pharmacology interacts with health system structures and regulatory environments[163]. In the United States, market-driven healthcare delivery, fragmented regulation, and aggressive pharmaceutical promotion amplified the risks associated with potent opioid drugs[164]. In contrast, European systems have generally prioritized centralized oversight, stronger gatekeeping, and harm reduction[165].

From a global health perspective, these differences illustrate how similar pharmacological agents can produce vastly different population-level outcomes

depending on contextual factors[166]. The opioid crisis is therefore not solely a consequence of drug properties but of the systems governing their use[167].

4.5 Lessons for pharmaceutical science and policy

The experience of high-income countries underscores the need for pharmaceutical development and regulation to be informed by real-world use patterns and long-term outcomes[168]. For pharmaceutical scientists, the crisis highlights the importance of developing safer analgesics, improved formulations, and non-opioid alternatives[169].

For policymakers, the crisis emphasizes the necessity of balancing access to pain relief with robust safeguards against misuse[170]. Surveillance systems, prescriber education, and harm reduction must be integral components of opioid policy[171].

4.6 Conclusion

The opioid crisis in high-income countries represents a cautionary example of how potent pharmacological tools can generate widespread harm when deployed without adequate controls. While the United States has borne the brunt of this crisis, European countries face emerging risks that warrant proactive and coordinated responses. Understanding these dynamics is essential for informing global strategies that seek to balance opioid access and safety, a challenge explored further in subsequent chapters.

Chapter 5 - Under-Access to Opioids in Low- and Middle-Income Countries

5.1 Introduction

While high-income countries have faced substantial harms from excessive opioid availability, the dominant challenge in low- and middle-income countries (LMICs) is the opposite: a persistent and severe lack of access to opioid analgesics for legitimate medical use. This under-access constitutes a major global health failure, resulting in widespread untreated pain, particularly among patients with cancer, advanced chronic illness, trauma, and postoperative needs. This chapter examines the structural, regulatory, and clinical determinants of opioid under-access in LMICs and explores its ethical and public health implications.

5.2 Scope and magnitude of opioid under-access

5.2.1 Global consumption disparities

International consumption data consistently demonstrate that LMICs account for only a minimal proportion of global opioid use despite representing the majority of the world’s population and a substantial share of the global burden of pain[172]. Many countries in sub-Saharan Africa, South Asia, and parts of Latin America report morphine-equivalent consumption levels that are orders of magnitude lower than those observed in high-income countries[173].

This disparity is particularly striking in the context of cancer-related pain[174]. Although cancer incidence and mortality are rising rapidly in LMICs, access to strong opioid analgesics remains extremely limited, leaving millions of patients without adequate pain relief at the end of life[175].

5.2.2 Populations most affected

The consequences of opioid under-access disproportionately affect vulnerable populations, including patients with advanced cancer, individuals requiring palliative care, children with severe pain conditions, and patients in rural or conflict-affected areas[176]. In many settings, the absence of opioids forces reliance on ineffective or inappropriate alternatives, resulting in prolonged suffering and diminished quality of life[177].

5.3 Regulatory barriers

5.3.1 International drug control regimes

The global regulatory environment governing opioids is shaped primarily by international drug control treaties, notably the Single Convention on Narcotic Drugs of 1961[178]. While the Convention explicitly recognizes the medical necessity of opioids, its emphasis on preventing misuse and diversion has often led to overly restrictive national interpretations[179].

In LMICs, limited regulatory capacity and fear of international non-compliance have contributed to stringent controls on opioid procurement, storage, prescribing, and dispensing[180]. These controls frequently exceed what is required to ensure safe use and effectively impede access for medical purposes[181].

5.3.2 National legislation and administrative burden

At the national level, complex licensing procedures, restrictive prescribing authority, and burdensome reporting requirements create substantial obstacles for healthcare providers[182]. In some countries, only a small number of specialists are authorized to prescribe opioids, and facilities must navigate lengthy approval processes to obtain limited quantities[183].

These administrative barriers discourage prescribing and contribute to chronic shortages, particularly in decentralized or resource-limited health systems[184].

5.4 Health system constraints

5.4.1 Supply chain limitations

Weak pharmaceutical supply chains represent a major barrier to opioid access in LMICs[185]. Challenges include inadequate forecasting, limited procurement capacity, poor distribution infrastructure, and stock management failures[186]. Interruptions in opioid supply are common, particularly in rural areas and peripheral health facilities[187].

Additionally, low demand driven by restrictive policies and limited prescriber confidence reduces incentives for manufacturers and distributors to supply opioid medicines to these markets[188].

5.4.2 Workforce and training gaps

A lack of training in pain management and palliative care further constrains opioid use in LMICs[189]. Many healthcare professionals receive minimal education on opioid

pharmacology, dosing, and risk management, leading to fear of adverse effects and reluctance to prescribe[190].

Misconceptions about addiction and respiratory depression are widespread and often reinforced by punitive regulatory environments[191]. These factors collectively contribute to a culture of opioid avoidance, even when clinically indicated[192].

5.5 Cultural and societal factors

Cultural attitudes toward pain, suffering, and opioid use also influence access[193]. In some contexts, pain is viewed as an inevitable part of illness or life, while opioid use is stigmatized due to associations with illicit drug use[194]. Patients and families may resist opioid therapy, and healthcare providers may internalize societal fears[195].

Stigma surrounding opioids can be particularly pronounced in countries that have experienced social or political harm related to drug trafficking, further complicating efforts to expand medical access[196].

5.6 Ethical and human rights considerations

The systematic failure to provide adequate pain relief raises profound ethical and human rights concerns[197]. Pain relief has been recognized by some scholars and international bodies as an essential component of the right to health[198]. Denial of access to essential opioid medicines may constitute a violation of human dignity and an instance of structural violence[199].

From a pharmaceutical and global health perspective, addressing opioid under­access is not merely a technical challenge but a moral imperative[200]. Policies that prioritize control at the expense of care risk perpetuating unnecessary suffering on a massive scale[201].

5.7 Case studies from low- and middle-income countries

5.7.1 India

India illustrates the complex interplay between regulation and access[202]. Despite being one of the world’s largest producers of pharmaceutical opioids, access within the country has historically been severely restricted[203]. Regulatory reforms in recent years have sought to simplify licensing procedures and expand access to morphine for palliative care, demonstrating the potential for policy change to improve outcomes[204].

5.7.2 Sub-Saharan Africa

In many sub-Saharan African countries, opioid availability remains extremely limited[205]. Successful initiatives in select countries have shown that targeted training, regulatory reform, and supply chain strengthening can significantly expand access to oral morphine, even in low-resource settings[206].

5.8 Implications for global health and pharmaceutical policy

The under-access to opioids in LMICs highlights the need for global strategies that explicitly prioritize equitable access to essential medicines[207]. Pharmaceutical policy must balance the legitimate need for control with the imperative to alleviate suffering[208].

Strengthening regulatory capacity, simplifying administrative procedures, investing in workforce training, and aligning international guidance with local realities are critical steps toward addressing this challenge[209].

5.9 Conclusion

Under-access to opioid analgesics in low- and middle-income countries represents a major yet often overlooked global health crisis. Structural, regulatory, and cultural barriers collectively deny millions of patients access to effective pain relief.

Addressing this inequity is essential to resolving the global opioid paradox and requires coordinated action across pharmaceutical science, health systems, and international policy.

Chapter 6 - Regulatory and Policy Frameworks Governing Opioid Use

6.1 Introduction

Regulatory and policy frameworks play a decisive role in shaping how opioid analgesics are manufactured, distributed, prescribed, and monitored worldwide. While the pharmacological properties of opioids are universal, their real-world impact varies substantially depending on how they are governed. This chapter examines the international, regional, and national regulatory architectures that influence opioid access and control, with particular attention to the roles of the United Nations drug control system, the World Health Organization (WHO), the European Medicines Agency (EMA), and national implementation mechanisms.

Understanding these frameworks is essential to explaining both the opioid crisis observed in high-income countries and the persistent under-access to opioids in low- and middle-income countries. The chapter highlights how regulatory intent, interpretation, and capacity interact with pharmaceutical science to produce divergent outcomes.

6.2 United Nations drug control system

6.2.1 The Single Convention on Narcotic Drugs (1961)

The cornerstone of global opioid regulation is the Single Convention on Narcotic Drugs of 1961, as amended by the 1972 Protocol[210]. The Convention seeks to balance two core objectives: ensuring the availability of narcotic drugs for medical and scientific purposes, and preventing their diversion, misuse, and abuse[211]. Opioid analgesics such as morphine, fentanyl, and oxycodone are classified under schedules that impose varying degrees of control[212].

While the Convention explicitly recognizes the indispensability of opioids for pain relief, its implementation has historically emphasized control over access[213]. Member States are required to establish national authorities, estimate medical needs, and report consumption data to the International Narcotics Control Board (INCB)[214]. In practice, limited technical capacity and fear of non-compliance have led many countries—particularly LMICs—to adopt overly restrictive measures that exceed treaty requirements[215].

6.2.2 Role of the International Narcotics Control Board

The INCB is tasked with monitoring treaty compliance and ensuring the balance between availability and control[216]. It collects national estimates of opioid requirements and issues annual reports assessing global consumption trends[217]. In recent years, the INCB has increasingly acknowledged the problem of inadequate access to opioid analgesics and has called for reforms to improve availability for medical use[218].

Despite these efforts, the perception of the INCB as a control-oriented body persists, and its guidance is often interpreted conservatively at the national level[219]. This dynamic illustrates how regulatory signaling can shape pharmaceutical access independently of formal legal texts[220].

6.3 World Health Organization and normative guidance

6.3.1 WHO Model List of Essential Medicines

The WHO Model List of Essential Medicines (EML) serves as a normative reference for national medicines policies[221]. Several opioid analgesics, including morphine, are designated as essential medicines due to their critical role in pain management and palliative care[222]. Inclusion on the EML signals that these medicines should be available at all times, in adequate amounts, and at affordable prices[223].

However, inclusion on the EML does not guarantee access[224]. National adoption varies widely, and regulatory barriers often prevent essential opioids from reaching patients[225]. The disconnect between normative guidance and operational reality is particularly pronounced in LMICs[226].

6.3.2 WHO guidelines on pain management

The WHO has issued multiple guidelines addressing cancer pain, palliative care, and the rational use of opioid analgesics[227]. These guidelines emphasize stepwise pain management, appropriate dosing, and risk mitigation strategies[228]. They also advocate for education and training of healthcare providers to reduce fear and misinformation surrounding opioid use[229].

While WHO guidance is influential, its non-binding nature means that implementation depends heavily on national political will and health system capacity[230].

6.4 European regulatory framework

6.4.1 Role of the European Medicines Agency

Within the European Union, the European Medicines Agency (EMA) is responsible for the scientific evaluation and supervision of medicinal products[231]. The EMA assesses the quality, safety, and efficacy of opioid medicines authorized through centralized procedures[232]. However, decisions related to prescribing, reimbursement, and controlled substance regulation remain largely within the competence of Member States[233].

The EMA has contributed to pharmacovigilance efforts related to opioid use, including the monitoring of misuse, abuse, and dependence[234]. Risk management plans and post-marketing surveillance requirements aim to identify and mitigate opioid-related harms[235].

6.4.2 EU-level coordination and limitations

Although the EU has facilitated coordination through pharmacovigilance systems and data sharing, there is no unified EU-wide opioid policy comparable to that of the United States[236]. This fragmentation has contributed to heterogeneous opioid use patterns across Europe, with varying levels of access and risk[237].

6.5 National implementation and policy variation

6.5.1 Prescribing regulations and monitoring

At the national level, opioid policy is operationalized through prescribing regulations, licensing systems, and monitoring mechanisms such as prescription drug monitoring programs (PDMPs)[238]. In high-income countries, these tools have been increasingly used to curb overprescribing and identify misuse[239].

In LMICs, however, similar regulatory instruments often function as barriers rather than safeguards, reflecting differences in infrastructure and administrative capacity[240].

6.5.2 Reimbursement and health system incentives

Reimbursement policies and health system incentives strongly influence opioid prescribing behavior[241]. In some settings, limited coverage of non-opioid pain management options has inadvertently encouraged opioid use, while in others, lack of reimbursement for opioids restricts access even when clinically indicated[242].

These dynamics underscore the importance of aligning regulatory control with broader health system design[243].

6.6 Regulatory tension: access versus control

A central theme emerging from this analysis is the persistent tension between ensuring access to essential opioid medicines and preventing misuse and diversion[244]. This tension is evident at all levels of governance, from international treaties to local prescribing rules[245].

Excessive focus on control can lead to under-treatment of pain, while insufficient safeguards can result in widespread harm[246]. Achieving balance requires regulatory frameworks that are informed by pharmacological evidence, responsive to epidemiological realities, and adaptable to local contexts[247].

6.7 Implications for pharmaceutical and regulatory science

For pharmaceutical scientists, regulatory frameworks shape incentives for drug development, formulation design, and post-marketing surveillance[248]. For regulators and policymakers, understanding opioid pharmacology is essential to designing proportionate and effective controls[249].

Bridging the gap between pharmaceutical science and regulatory practice is critical to resolving the global opioid paradox identified in this thesis[250].

6.8 Conclusion

Regulatory and policy frameworks exert a profound influence on opioid access and use worldwide. International treaties, WHO guidance, regional regulatory bodies, and national implementation mechanisms collectively shape the balance between availability and control. Misalignment among these layers has contributed to both opioid overuse in high-income countries and severe under-access in LMICs. Addressing these challenges requires regulatory approaches that are evidence­based, context-sensitive, and explicitly oriented toward both public health protection and the alleviation of suffering.

Chapter 7 - Pharmacological and Policy-Based Solutions

7.1 Introduction

The preceding chapters have demonstrated that the global opioid paradox— characterized by overuse and opioid-related harm in high-income countries and severe under-access in low- and middle-income countries—cannot be resolved through pharmacological or regulatory approaches alone. Effective solutions must integrate advances in pharmaceutical science with evidence-based policy interventions that are sensitive to health system capacity and population needs. This chapter explores pharmacological innovations and policy-based strategies aimed at achieving a balanced approach to opioid access, safety, and equity.

7.2 Pharmacological solutions

7.2.1 Development of safer opioid molecules

One major avenue of pharmaceutical innovation involves the development of opioid molecules with improved safety profiles[251]. Research into biased p-opioid receptor agonists seeks to preferentially activate analgesic G protein-mediated pathways while minimizing p-arrestin-related adverse effects such as respiratory depression and constipation[252]. Although early clinical results have been mixed, this approach represents a promising direction for future drug development[253].

Partial agonists, such as buprenorphine, also offer advantages due to their ceiling effect on respiratory depression[254]. Their pharmacodynamic properties make them valuable not only for pain management but also for the treatment of opioid use disorder, particularly in settings with limited monitoring capacity[255].

7.2.2 Abuse-deterrent formulations

Abuse-deterrent formulations (ADFs) have been developed to reduce the potential for opioid misuse through manipulation, such as crushing or dissolving tablets for non­oral administration[256]. These formulations incorporate physical and chemical barriers or antagonist components designed to limit euphoric effects when misused[257].

While ADFs may reduce certain forms of prescription opioid abuse, their overall impact on population-level harm remains contested[258]. Furthermore, their higher cost may limit applicability in LMICs, underscoring the need for context-specific solutions[259].

7.2.3 Non-opioid and adjunctive analgesics

Expanding access to effective non-opioid analgesics and multimodal pain management strategies is critical to reducing reliance on opioids[260]. Pharmacological alternatives include non-steroidal anti-inflammatory drugs, anticonvulsants, antidepressants, and emerging agents targeting novel pain pathways[261].

From a global health perspective, integrating non-opioid therapies into essential medicines lists and clinical guidelines can help optimize pain management while minimizing opioid exposure[262].

7.3 Policy-based solutions

7.3.1 Balanced opioid policy frameworks

Balanced opioid policies explicitly recognize the dual imperatives of access and control[263]. Such frameworks aim to ensure the availability of opioids for legitimate medical use while implementing proportionate safeguards against misuse[264]. Key components include evidence-based prescribing guidelines, streamlined procurement processes, and rational scheduling of opioid medicines[265].

International organizations, including the WHO and INCB, have increasingly advocated for balanced approaches that align drug control objectives with public health goals[266].

7.3.2 Regulatory reform in low- and middle-income countries

In LMICs, regulatory reform is essential to expanding access to opioid analgesics[267]. Simplifying licensing procedures, expanding prescriber authority, and reducing administrative burdens can significantly improve availability without compromising safety[268]. Successful reforms in countries such as India demonstrate that targeted policy changes can yield substantial gains in access[269].

Capacity-building initiatives, including training for regulators and healthcare providers, are critical to ensuring that reforms translate into improved clinical practice[270].

7.3.3 Harm reduction strategies in high-income countries

In high-income countries, harm reduction strategies play a central role in mitigating opioid-related harms[271]. These include opioid substitution therapy, widespread availability of naloxone for overdose reversal, supervised consumption facilities, and prescription monitoring programs[272].

Such interventions have demonstrated effectiveness in reducing mortality and morbidity and highlight the importance of treating opioid use disorder as a public health issue rather than solely a criminal justice concern[273].

7.4 Integrating pharmacology and policy

Effective opioid policy must be informed by pharmacological evidence[274]. Understanding differences in potency, half-life, and metabolic pathways can guide rational scheduling, prescribing limits, and risk management strategies[275].

Conversely, regulatory environments influence pharmaceutical innovation by shaping incentives for the development of safer analgesics[276].

An integrated approach that aligns pharmacological advances with adaptive policy frameworks offers the greatest potential to resolve the global opioid paradox[277].

7.5 Global health equity considerations

Ensuring equitable access to pain relief is a core global health objective[278]. Solutions must account for disparities in health system capacity, resource availability, and cultural context[279]. In LMICs, low-cost, scalable interventions—such as oral morphine programs coupled with provider training—may yield the greatest impact[280].

Equity-focused approaches also require addressing stigma and misinformation surrounding opioid use through community engagement and education[281].

7.6 Future directions and research priorities

Future research should prioritize the development of analgesics with improved safety profiles, the evaluation of policy interventions in diverse settings, and the integration of pharmacogenomics into pain management strategies[282]. Strengthening data collection on opioid use and outcomes in LMICs is particularly important to inform evidence-based policy[283].

Interdisciplinary collaboration among pharmaceutical scientists, clinicians, policymakers, and global health experts will be essential to advancing these priorities[284].

7.7 Conclusion

Pharmacological and policy-based solutions to the global opioid crisis must be pursued in tandem. Advances in drug development alone are insufficient without supportive regulatory and health system frameworks, while policy interventions must be grounded in pharmacological science. By integrating these approaches, it is possible to move toward a more balanced, equitable, and effective global strategy for opioid use and pain management.

Chapter 8 - Discussion

8.1 Integrating pharmacology, global health, and policy

This thesis set out to examine opioid use through an integrated lens that combines pharmaceutical sciences, global health, and regulatory policy. The preceding chapters have demonstrated that neither opioid-related harm nor opioid under-access can be adequately understood in isolation. Instead, both phenomena emerge from the interaction between the intrinsic pharmacological properties of opioids and the extrinsic systems that govern their availability, prescribing, and monitoring.

At the pharmacological level, opioids are uniquely effective analgesics due to their potent action on p-opioid receptors and their ability to modulate nociceptive pathways at multiple levels of the nervous system. At the same time, these same properties confer significant risks, including tolerance, dependence, and respiratory depression. These dual characteristics make opioids particularly sensitive to policy environments: small changes in availability, formulation, or prescribing norms can produce large population-level effects.

8.2 Pharmacology as a driver of population-level outcomes

One of the central insights emerging from this work is that opioid pharmacology directly shapes public health outcomes[285]. High receptor efficacy, rapid central nervous system penetration, and variable pharmacokinetics contribute to both therapeutic benefit and overdose risk[286]. In high-income countries, the widespread use of high-potency and long-acting opioids amplified these risks, particularly when combined with permissive prescribing cultures and insufficient post-marketing surveillance[287].

Conversely, in low-resource settings, the same pharmacological complexity has been interpreted as justification for extreme caution or outright restriction[288]. Limited capacity to manage adverse effects, monitor dosing, or treat overdose has reinforced regulatory conservatism, resulting in systematic under-treatment of pain[289]. Thus, pharmacology has functioned not only as a scientific determinant of drug effect but also as a policy signal influencing access decisions[290].

8.3 Global health inequities and the opioid paradox

The global opioid paradox—simultaneous overuse and underuse across different regions—represents a stark manifestation of global health inequity[291]. Chapters 3 through 5 demonstrated that opioid consumption bears little relationship to the global burden of pain. Instead, consumption patterns reflect economic capacity, regulatory interpretation, and health system strength.

From a global health perspective, this misalignment raises fundamental questions about equity, justice, and the right to health[292]. In high-income countries, excess opioid exposure has disproportionately affected socially and economically marginalized populations[293]. In low- and middle-income countries, lack of access has denied millions of patients basic pain relief, particularly at the end of life[294]. Both outcomes represent failures of health systems to equitably translate pharmacological knowledge into humane care[295].

8.4 Role of regulatory and policy frameworks

Regulatory frameworks emerged as a critical mediating factor between opioid pharmacology and health outcomes[296]. International drug control treaties were designed to balance access and control but have often been implemented in ways that privilege prohibition over care[297]. The analysis in Chapter 6 showed how conservative interpretations of international obligations, combined with limited regulatory capacity, have entrenched barriers to access in many LMICs[298].

In contrast, the opioid crisis in high-income countries illustrates how insufficiently restrictive policies, coupled with commercial incentives and fragmented oversight, can lead to widespread harm[299]. These contrasting experiences underscore that regulatory failure can occur at both extremes—through over-regulation and under- regulation—and that effective governance requires proportionality and adaptability[300].

8.5 Evaluating proposed solutions

Chapter 7 outlined a range of pharmacological and policy-based solutions aimed at resolving the global opioid paradox. The discussion here highlights that no single intervention is sufficient. Pharmacological innovations, such as biased agonists or abuse-deterrent formulations, may reduce certain risks but cannot compensate for weak health systems or inappropriate policy environments.

Similarly, policy reforms that expand access without parallel investment in training, supply chain management, and harm reduction risk replicating patterns of misuse. The most promising approaches are those that integrate scientific evidence with context-specific policy design, such as oral morphine programs linked to palliative care training or harm reduction strategies embedded within broader public health frameworks.

8.6 Implications for pharmaceutical sciences

For the field of pharmaceutical sciences, this thesis highlights the importance of considering real-world use and policy context as integral components of drug development and evaluation. Opioids exemplify how pharmacokinetic and pharmacodynamic properties can have far-reaching implications beyond individual patients, influencing regulatory decisions and population health.

Future pharmaceutical innovation should prioritize safety, predictability, and suitability for diverse health system contexts. This includes not only molecular design but also formulation, delivery mechanisms, and post-marketing surveillance strategies.

8.7 Implications for global health and policy

From a global health perspective, addressing opioid inequities requires reframing pain relief as a core component of universal health coverage. Policies must explicitly recognize untreated pain as a public health and ethical concern, rather than a collateral issue of drug control.

Strengthening regulatory capacity, aligning international guidance with local realities, and fostering collaboration between health and drug control authorities are essential steps toward more equitable opioid policy. Importantly, global health actors must engage with pharmaceutical science to ensure that policy decisions are grounded in evidence rather than fear.

8.8 Limitations of the study

This thesis is primarily based on secondary data and literature analysis, which limits the ability to draw causal inferences or assess the effectiveness of specific interventions in real time. Data gaps, particularly in LMICs, constrain the precision of consumption and outcome estimates. Nevertheless, the integrative approach adopted here provides a robust conceptual framework for understanding the global opioid paradox.

8.9 Conclusion

The discussion synthesizes evidence from pharmacology, epidemiology, and policy to demonstrate that the global opioid crisis is not a singular phenomenon but a spectrum of failures rooted in misaligned systems. Opioids are neither inherently benevolent nor inherently harmful; their impact is determined by how pharmacological properties are mediated through regulatory and health system structures.

Resolving the global opioid paradox requires moving beyond polarized debates toward integrated, evidence-based strategies that balance access with safety and equity with control. This integrative perspective forms the foundation for the conclusions and recommendations presented in the final chapter of this thesis.

Chapter 9 - Conclusions and Recommendations

9.1 Overall conclusions

This thesis examined opioid use through an integrated pharmaceutical, global health, and regulatory lens, with the objective of understanding and addressing the global opioid paradox. The analysis demonstrated that opioids are indispensable medicines for the treatment of moderate to severe pain, yet their benefits and harms are profoundly shaped by the systems that govern their use. Neither the opioid crisis observed in high-income countries nor the severe under-access in low- and middle­income countries can be attributed solely to pharmacology; rather, both outcomes emerge from misalignment between drug properties, regulatory frameworks, and health system capacities.

At the pharmacological level, opioids possess unique analgesic efficacy mediated primarily through p-opioid receptor activation, alongside well-documented risks including tolerance, dependence, and respiratory depression. These intrinsic characteristics necessitate careful regulation but do not justify blanket restriction. At the population level, the thesis demonstrated that opioid consumption patterns are poorly correlated with the global burden of pain, revealing deep inequities in access to essential medicines.

The findings confirm that global opioid governance has struggled to strike an appropriate balance between access and control. Overly permissive environments have enabled widespread harm in some settings, while excessively restrictive interpretations of drug control obligations have produced unnecessary suffering in others. Addressing this imbalance is both a scientific and moral imperative.

9.2 Key contributions of the thesis

This work makes several contributions to pharmaceutical sciences and global health scholarship. First, it provides an interdisciplinary framework that explicitly links opioid pharmacology to regulatory decision-making and population health outcomes. Second, it situates opioid-related harms and under-treatment of pain within a shared analytical model, rather than treating them as separate or competing problems. Third, it highlights the central role of policy interpretation and implementation in shaping real-world drug effects, thereby extending the scope of pharmaceutical science beyond laboratory and clinical domains.

By integrating pharmacokinetics, pharmacodynamics, epidemiological data, and policy analysis, this thesis contributes to a more holistic understanding of medicines as social as well as biological interventions.

9.3 Recommendations for policy and regulation

9.3.1 Rebalancing international drug control

International drug control bodies should continue to emphasize that ensuring access to opioid analgesics for medical and scientific purposes is a legal obligation under existing treaties[301]. Clearer guidance and technical assistance are needed to help countries align national regulations with this mandate without compromising safety[302]. The role of the INCB should evolve further toward facilitation and capacity-building rather than predominantly compliance monitoring[303].

9.3.2 Strengthening national regulatory capacity

Countries should invest in regulatory systems that are proportionate, evidence­based, and adaptable to local health system capacity[304]. Simplifying procurement and prescribing processes, expanding authorized prescriber pools, and improving supply chain reliability can significantly enhance access in under-resourced settings[305]. In high-income countries, regulatory reforms should prioritize rational prescribing, monitoring, and harm reduction rather than punitive approaches[306].

9.3.3 Integrating pain management into universal health coverage

Pain relief and palliative care should be explicitly incorporated into universal health coverage strategies[307]. Reimbursement policies must support both opioid and non­opioid pain management options, and training in pain management should be integrated into health professional education[308]. Recognizing untreated pain as a public health issue is essential to reducing global inequities[309].

9.4 Recommendations for pharmaceutical research and practice

Pharmaceutical research should continue to pursue the development of analgesics with improved safety profiles, including partial agonists, biased ligands, and novel non-opioid therapies[310]. Greater attention should be paid to formulation and delivery methods that enhance safety and suitability for diverse settings[311].

Post-marketing surveillance and real-world evidence generation should be strengthened to inform adaptive regulation[312]. Pharmaceutical scientists and industry actors have a responsibility to engage transparently with regulators and public health authorities to ensure that innovation aligns with societal needs[313].

9.5 Recommendations for global health action

Global health organizations should prioritize pain management as an essential component of health system strengthening[314]. This includes supporting education and training, combating stigma surrounding opioid use, and facilitating South-South and North-South knowledge exchange[315]. Data collection on pain prevalence, opioid use, and outcomes must be improved, particularly in low- and middle-income countries[316].

Collaborative, interdisciplinary approaches that bridge pharmaceutical science, clinical practice, and policy are critical to achieving sustainable progress[317].

9.6 Future research directions

Future research should focus on evaluating integrated pharmacological and policy interventions in diverse contexts, including pragmatic trials and implementation science studies. The role of pharmacogenomics in individualized pain management and the long-term population impacts of regulatory reforms warrant further investigation.

Expanding high-quality data collection in under-represented regions will be essential to refining global opioid policy and ensuring equitable access to pain relief.

9.7 Final remarks

Opioids occupy a unique and contested space at the intersection of medicine, regulation, and ethics. This thesis argues that resolving the global opioid paradox requires moving beyond polarized narratives toward balanced, evidence-based strategies that respect both the need to alleviate suffering and the obligation to protect public health.

By integrating pharmacological science with global health principles and regulatory insight, this work aims to contribute to more humane, equitable, and effective opioid policy worldwide.

Bibliographic references

1. World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Geneva: World Health Organization; 2018.

2. Knaul FM, Farmer PE, Krakauer EL, Alwan A, Bhadelia A, Gralow JR, et al. Alleviating the access abyss in palliative care and pain relief—an imperative of universal health coverage: the Lancet Commission report. Lancet. 2018;391(10128):1391-1454.

3. Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education; 2018.

4. World Health Organization. The selection and use of essential medicines: Report of the WHO Expert Committee, 2023. Geneva: World Health Organization; 2023.

5. Pasternak GW, Pan YX. Mu opioid receptors in pain management. Mol Pharmacol. 2013;83(3):552-561.

6. Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education; 2018.

7. Kolodny A, Courtwright DT, Baldwin PG, et al. The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559-574.

8. Case A, Deaton A. Deaths of Despair and the Future of Capitalism. Princeton: Princeton University Press; 2020.

9. Dasgupta N, Beletsky L, Ciccarone D. Opioid Crisis: No Easy Fix to Its Social and Economic Determinants. Am J Public Health.

2018;108(2):182-186.

10. Farmer PE. An anthropology of structural violence. Curr Anthropol. 2004;45(3):305-325.

11. Manjiani D, Paul DB, Kunnumpurath S, et al. Availability and utilization of opioids for pain management in global health. Ochsner J.

2014;14(2):203-207.

12. Rajagopal MR. The morphine manifesto. Indian J Palliat Care. 2007;13(1):1-3.

13. Fisher B, Keates L, Guarinieri M, et al. Facing the opioid overdose crisis in North America: Strategic lessons for the European context. Int J Drug Policy. 2020;79:102716.

14. Hassan J, Hussain S. Pharmaceutical Regulation and Opioid Accessibility in South Asia: A Comparative Policy Review. Health Policy Plan. 2022;37(4):512-524.

15. DeBaun B. The Role of the World Health Organization in Global Health Policy and Regulation. J Public Health Policy. 2021;42(3):456-468.

16. Pathan H, Williams J. Basic opioid pharmacology: An update. Br J Pain. 2012;6(1):11-16.

17. Snyder SH, Pasternak GW. Historical review: Opioid receptors. Trends Pharmacol Sci. 2003;24(4):198-205.

18. Kaye AD, Jones MR, Kaye AM, et al. Prescription Opioid Abuse in Chronic Pain: An Updated Review of Opioid Abuse Predictors and Strategies to Curb Opioid Abuse. Pain Physician. 2017;20(2S):S93- S109.

19. Fine DR, Herzberg D, Wakeman SE. Societal Biases, Institutional Discrimination, and Trends in Opioid Use in the USA. J Gen Intern Med. 2021;36(3):797-801.

20. Ooms GI, van Oirschot J, de Kant D, et al. Barriers to accessing internationally controlled essential medicines in sub-Saharan Africa: A scoping review. Int J Drug Policy. 2023;118:104078.

21. O’Brien M, Bivol S, Moore THM, et al. How Drug Control Policy and Practice Undermine Access to Controlled Medicines. Health Hum Rights. 2024;26(1):145-158.

22. Langford AV, Lin CW, Nielsen S. Global perspectives on opioid use: shifting the conversation from deprescribing to quality use of medicines. BMJ Qual Saf. 2024;34(3):143-145.

23. Sharma S, Blyth FM, Mishra SR, Briggs AM. Health system strengthening is needed to respond to the burden of pain in low- and middle-income countries and to support healthy ageing. J Glob Health. 2019;9(2):020317.

24. Ravinetto R, Henriquez R, Srinivas PN, et al. Shaping the future of global access to safe, effective, appropriate and quality health products. BMJ Glob Health. 2024;9(1):e014425.

25. Alharbi NS, Al-Habas SM, Alsharekh AA, et al. Pharmaceutical sciences and social dynamics: bridging medication practices, public health challenges, and everyday lives. Int J Health Sci.

2024;8(S1):1690-1712.

26. Almotairi BA, Alharbi MO, Alanazi AS, et al. Interdisciplinary approaches to the opioid crisis: optimizing pain management through nurse-pharmacist collaboration. Int J Health Sci. 2024;8(S1):1777-1799.

27. Bérubé M, Côté C, Gagnon MA, et al. Interdisciplinary strategies to prevent long-term and detrimental opioid use following trauma: a stakeholder consensus study. Pain Med. 2023;24(8):933-940.

28. Stein C. Opioid Receptors. Annu Rev Med. 2016;67:325-340.

29. Ossipov MH, Dussor GO, Porreca F. Central modulation of pain. J Clin Invest. 2010;120(11):3779-3787.

30. Dahan A, van der Schrier R, Smith T, Aarts L, van Velzen M, Niesters M. A Review of the Control of Breathing in Clinical Settings: Recent Theoretical and Practical Advances. Anesthesiology. 2024;140(4):841- 858.

31. Valentino RJ, Volkow ND. Untangling the complexity of opioid receptor function. Neuropsychopharmacology. 2018;43(13):2514-2520.

32. Singhal BK, Kumar P, Kohli K. Biased agonism: A novel paradigm in opioid pharmacology to decouple analgesia from side effects. Indian J Pharmacol. 2021;53(6):483-491.

33. Gillis TE, Cassell RJ, Vaughan CW, et al. Intrinsic efficacy and the development of tolerance to opioids: A review of the current evidence. Front Pharmacol. 2020;11:584661.

34. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1(1):13-20.

35. Stevens CW. Opioid receptor evolution. Vitam Horm. 2023;123:1-25.

36. Corder G, Castro DC, Bruchas MR, Scherrer G. Endogenous and exogenous opioid reward systems of the brain. Annu Rev Neurosci. 2018;41:453-473.

37. Toll L, Bruchas MR, Calo’ G, Cox BM, Zaveri NT. Nociceptin/Orphanin FQ Receptor Structure, Signaling, and Pharmacology: Update on the IUPHAR Database. Pharmacol Rev. 2016;68(2):415-457.

38. Zaki GW, Shokouhmand A, Kelly E, Henderson G. The Mu-Opioid Receptor: Agonist-induced Receptor Desensitization and Internalization. Front Pharmacol. 2024;15:1352461.

39. Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, et al. Regulation of Mu-Opioid Receptors: Desensitization, Phosphorylation, Internalization, and Tolerance. Pharmacol Rev. 2013;65(1):223-254.

40. Bruchas MR, Chavkin C. Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology (Berl).

2010;210(2):137-147.

41. Gendron L, Mittal N, Beaudry H, Walwyn W. The Delta-Opioid Receptor: An Evolving Target for the Treatment of Chronic Pain and its Comorbidities. Front Pharmacol. 2024;15:1353245.

42. Kiviniemi VJ, Jarvela IY, Tuovinen T, et al. Global distribution of opioid receptors in the human brain: A high-resolution PET study. J Neurosci. 2024;44(2):e089223.

43. Mansour A, Fox CA, Akil H, Watson SJ. Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci. 1995;18(1):22-29.

44. Benarroch EE. Opioid system: basic concepts and involvement in Pain and non-pain regions. Neurology. 2022;98(12):494-503.

45. Manglik A, Kruse AC, Kobilka BK, et al. Crystal structure of the p-opioid receptor bound to a morphinan antagonist. Nature.

2012;485(7398):321-326.

46. Law PY, Wong YH, Loh HH. Molecular mechanisms and regulation of opioid receptor signaling. Annual Review of Pharmacology and Toxicology. 2000;40:215-230.

47. Zamponi GW, Currie KP. Regulation of voltage-gated calcium channels by G protein-coupled receptors. Channels (Austin). 2013;7(5):324-333.

48. Kohno T, Ji RR, Moore KA, Woolf CJ. Peripheral axonal injury sensitizes antigen-presenting cells in the spinal cord and enhances opioid-induced presynaptic inhibition. Journal of Neuroscience. 2005;25(5):1173-1181.

49. Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol. 2008;154(2):384-396.

50. Kenakin T. Biased Agonism as a Fundamental Drug Property. Cardiovasc Drugs Ther. 2024;38(1):5-15.

51. DeWire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the p-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013;344(3):708-717.

52. Bohn LM, Lefkowitz RJ, Gainetdinov RR, et al. Enhanced morphine- induced analgesia, winthin-dose tolerance, and gi-protein activation in beta-arrestin 2-deficient mice. Science. 1999;286(5449):2495-2498.

53. Chen X, Gauthier AD, Fossler MJ, et al. Oliceridine: A Next-Generation p-Opioid Receptor G-Protein Pathway-Selective Agonist for the Management of Moderately Severe Acute Pain. J Clin Pharmacol. 2024;64(2):147-160.

54. Kliewer A, Gillis A, Cassel R, et al. Morphine-induced respiratory depression is independent of beta-arrestin2 in mice. British Journal of Pharmacology. 2020;177(13):2923-2931.

https://doi.org/10.1111/bph. 15004

55. Agla C, Martus P, Stein C. Peripheral opioid receptors in human extraabdominal surgery. Pain. 2014;155(10):2056-2061.

56. Heinke B, Gingl E, Sandkuhler J. Multiple targets of p-opioid receptor- mediated presynaptic inhibition at primary afferent Adelta- and C-fibers. J Neurosci. 2011;31(4):1313-1322.

57. Lau BK, Vaughan CW. Descending modulation of pain: the GABA- disinhibition hypothesis of magnesium-induced analgesia. Curr Opin Neurobiol. 2014;29:159-164.

58. Volpe DA, McMahon Tobin GA, Mellon RD, et al. Uniform assessment of efficacy of p-opioid receptor agonists: utilizing receptor heterogeneity and intrinsic efficacy. FEBS Lett. 2011;585(15):2390-2396.

59. Lotsch J, Skarke C, Liefhold J, Geisslinger G. Genetic predictors of the clinical response to opioid analgesics: clinical evidence and knowledge gaps. Trends Mol Med. 2004;10(3):135-143.

60. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther. 1998;64(6):603-611.

61. Dumas EO, Pollack GM. Opioid tolerance development: a pharmacokinetic/pharmacodynamic perspective. AAPS J. 2008;10(4):537-551.

62. Whistler JL, Chuang HH, Chu P, Jan LY, von Zastrow M. Morphine- activated opioid receptors elude desensitization and endocytosis. Neuron. 1999;23(4):737-746.

63. Melief EJ, Miyatake M, Bruchas MR, Chavkin C. Ligand-directed junk activation of p38 MAPK is required for naloxone-precipitated withdrawal and opioid-induced aversive self-administration. Neuron.

2010;65(6):777-786.

64. Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3(8):760-773.

65. Hanack C, Moroni M, Lima WC, Wende H, Kirchner M, Adelfinger L, et al. GABAergic Control of Neocortical Layer 1 VIP Interneurons Shapes Nociceptive Behavior. J Neurosci. 2015;35(3):1135-1145.

66. Wise RA, Robble MA. Dopamine and Addiction. Annu Rev Psychol. 2020;71:79-106.

67. Pattinson KT. Opioids and the control of respiration. Br J Anaesth. 2008;100(6):747-758.

68. De Schepper HU, Cremer A, Beutels M, et al. Opioid-induced constipation: mechanisms, surveillance, and management. Front Psychiatry. 2023;14:1225838.

69. Vuong C, Van Uum SH, O'Dell LE, Lutfy K, Friedman TC. The effects of opioids and opioid analogs on animal and human endocrine systems. Endocr Rev. 2010;31(1):98-132.

70. Nafziger AN, Barkin RL. Opioid therapy in populations with a history of substance use disorder. J Clin Pharmacol. 2018;58(10):1245-1256.

71. Saunders KW, Dunn KM, Merrill JO, et al. Relationship of opioid use and dosage levels to risk of fatal and nonfatal drug overdose. Arch Intern Med. 2010;170(7):645-651.

72. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613-624.

73. Brunton LL, Hilal-Dandan R, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw-Hill Education; 2018.

74. Trescot AM, Datta S, Lee M, Hansen H. Opioid pharmacology. Pain Physician. 2008;11(2 Suppl):S133-53.

75. Foster D, Somogyi AA, Bochner F. Methadone N-demethylation in human liver microsomes: role of cytochrome P450 enzymes. Br J Clin Pharmacol. 1999;47(4):403-12.

76. Stanley TH. The fentanyl story. J Pain. 2014;15(12):1215-26. doi:10.1016/j.jpain.2014.08.010

77. Hajj A, Khabbaz L, Laplanche JL, Peoc'h K. Pharmacogenetics of opiates: clinical implications. Pharmacogenomics. 2013;14(10):1199- 214.

78. Roeckel LA, Le Coz GM, Gaveriaux-Ruff C, Simonin F. Morphine-3- glucuronide: a review of its pharmacological properties. Front Pharmacol. 2020;11:604522.

79. Ballas SK. Voxelotor modulates the analgesic effect of certain opioids. J Clin Med Res. 2021;13(2):123-6.

80. Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of opioids. In: Evers AS, Maze M, Kharasch ED, editors. Anesthetic Pharmacology. 2nd ed. Cambridge: Cambridge University Press; 2011. p. 531-56.

81. Aegis Sciences Corporation. Clinical reference guide: opioid metabolism. Nashville, TN: Aegis; 2019.

82. Mikus G, Klimas J. Opioid metabolism and the risk of toxic accumulation in renal failure. J Clin Pharmacol Ther. 2017;55(4):312- 22.

83. Pasternak GW. The pharmacodynamics of interindividual opioid variation. Open Pain J. 2014;7(Suppl 1):31-7.

84. Lotsch J, Geisslinger G. Relevance of pharmacogenetics for clinical opioid therapy. Eur J Clin Pharmacol. 2011;67(2):117-25.

85. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351(27):2827-31.

86. Caudle KE, Dunnenberger HM, Freimuth RR, et al. Challenges in implementing pharmacogenetics into the clinical setting. Curr Drug Metab. 2014;15(2):209-17.

87. Webster LR. Risk factors for opioid-related overdose and mortality. J Pain Res. 2017;10:1569-77.

88. Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology.

2010;112(1):226-38.

89. Berterame S, Erthal J, Thomas J, et al. Use of opioid analgesics in the treatment of cancer pain: a world-wide perspective. Lancet. 2016;387(10028):1644-56.

90. Cleary J, Radbruch L, Torode J, Cherny NI. Next steps in access and availability of opioids for the treatment of cancer pain: reaching the 85%. Ann Oncol. 2013;24(Suppl 11):xi13-xi18.

91. Lohman D, Schleifer R, Amon JJ. Access to pain treatment as a human right. BMC Med. 2010;8:8.

92. Pettus K. Untreated pain in the lower and middle-income countries. Swansea: Global Drug Policy Observatory; 2013. Situation Analysis No. 1.

93. Shanthanna H, Ladha KS, Kehlet H, Joshi GP. Perioperative opioid administration: a critical review of institutional policies and system-level interventions. BMC Health Serv Res. 2022;22(1):329.

94. Rice AS, Smith BH, Blyth FM. The global burden of pain: the GBD 2015 and 2016 studies. Pain. 2016;157(4):791-6.

95. Fatoye F, Gebrye T, Odeyemi I. Real-world economic burden of low back pain: a systematic review. J Pain Res. 2019;12:1291-310.

96. Jackson TP, Gaeta R. Pain management in the developing world. Med Clin North Am. 2016;100(1):213-25.

97. Glajchen M. Chronic pain: the commonest cause of disability. Br J Clin Pharmacol. 2001;52(3):223-4.

98. Uwumiro FO, Udoh UA, Akinyemi O, et al. Global prevalence of cancer pain in the 21st century: a systematic review. J Cancer Policy. 2022;32:100327.

99. Neufeld NJ, Elnahal SM, Alvarez RH. Cancer pain: a review of epidemiology, clinical quality and value. Future Oncol. 2017;13(9):823- 32.

100. Harding R, Gwyther L, Mwangi-Powell FN. Palliative care in Sub­Saharan Africa. Lancet. 2013;381(9874):1251-3.

101. Rajagopal MR, Mazza D, Lipman AG. Palliative care in India: a huge need and a huge challenge. J Pain Palliat Care Pharmacother. 2003;17(3-4):119-30.

102. Cleary J, Maurina T, Fraser V. Access to opioid analgesics in the developing world. In: Bruera E, editor. Textbook of Palliative Medicine. Boca Raton: CRC Press; 2015. p. 112-25.

103. Seyler T, Giraudtiere L, Vicini R, et al. Defined daily doses (DDD) as a tool for comparing opioid consumption: a technical critique. Pharmacoepidemiol Drug Saf. 2014;23(S1):45-6.

104. International Narcotics Control Board. Report of the International Narcotics Control Board on the availability of internationally controlled medicines. Vienna: United Nations; 2022.

105. Nielsen S, Gisev N, Larance B, et al. Limitations of using MME for clinical and regulatory decision-making. Lancet Public Health. 2017;2(12):e539.

106. King NB, Fraser V, Boikos C, et al. Determinants of opioid consumption in low- and middle-income countries. PLoS One. 2014;9(3):e91589.

107. Berterame S, Erthal J. Evaluating global trends in opioid analgesics: 20 years of INCB data. Vienna: INCB Press; 2018.

108. Duthey B, Scholten W. Adequacy of opioid analgesic consumption at country, regional, and global levels. J Pain Symptom Manage. 2014;47(2):283-97.

109. Manjiani D, Paul DB, Kunnumpurath S, et al. Availability and utilization of opioids for pain management: global issues. Ochsner J. 2014;14(2):208-15.

110. Seya MJ, Gelders SF, Achara OU, et al. A first comparison between the consumption of and the need for opioid analgesics at country, regional, and global levels. J Pain Palliat Care Pharmacother. 2011;25(1):6-18.

111. Logie CH, Williams DJ. Palliative care and the cancer burden in low-income settings. Glob Health Action. 2015;8:26543.

112. Knaul FM, Farmer PE, Krakauer EL, et al. Alleviating the access abyss in palliative care and pain relief—an imperative of universal health coverage: the Lancet Commission report. Lancet.

2018;391(10128):1391-454.

113. Sullivan MD, Howe CQ. Opioid therapy for chronic pain in the US: promises and perils. Pain. 2013;154(Suppl 1):S94-100.

114. Meldrum ML. The pharmacist’s role in the "pain as the fifth vital sign" movement. J Am Pharm Assoc. 2016;56(5):493-5.

115. Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med.

2015;372(3):241-8.

116. Ciccarone D. The rise of illicitly manufactured fentanyl: the third wave of the opioid overdose epidemic in the United States. PLoS Med. 2019;16(1):e1002737.

117. Guy GP, Zhang K, Bohm MK, et al. Vital signs: changes in opioid prescribing in the United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(26):697-704.

118. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-31.

119. Volkow ND, McLellan AT. Opioid abuse in chronic pain— misconceptions and mitigation strategies. N Engl J Med. 2016;374(13):1253-63.

120. Vijayan R. Managing pain in low-resource settings: beyond the drugs. Singapore Med J. 2011;52(3):141-5.

121. Maurina T. Legislative barriers to access: narcotics control in Southeast Asia. Int J Drug Policy. 2013;24(6):546-51.

122. Eide PK. Low-cost monitoring of pain in remote settings. Glob Health Sci Pract. 2014;2(3):311-9.

123. Krakauer EL, Wenk R, Buitrago R, et al. Palliative care in Latin America: a report on the regional barriers. J Palliat Med.

2014;17(4):431-7.

124. O’Brien T, Gazelle G, Ward-Abel N. Educational deficits in pain management: a global perspective. Eur J Cancer Care. 2014;23(4):444- 52.

125. Brennan F, Lohman D, Gwyther L. Access to pain management as a human right. Am J Public Health. 2019;109(1):61-5.

126. Farmer PE, Gastineau HK. Structural violence and the relief of suffering. In: Infections and Inequalities. Berkeley: University of California Press; 1999. p. 231-50.

127. Mwangi-Powell FN. Pain relief: a fundamental right for all patients. Ecancermedicalscience. 2011;5:208.

128. Cherny NI, Radbruch L. The global opioid paradox: a call to action. Ann Oncol. 2010;21(11):2131-3.

129. Paice JA. Global access to pain relief: the paradox of opioid availability. JAMA Oncol. 2016;2(11):1405-6.

130. Scholten W, Christensen AE. Two parallel crises: the overdose crisis and the untreated pain crisis. Drugs Health Serv Res. 2021;1:100004.

131. Kishore SP, Siegel K. Global pain management: a pharmacologic and policy imperative. Glob Heart. 2012;7(3):255-60.

132. Smith T. Designing delivery systems for low-resource settings. Pharm Res. 2016;33(10):2341-5.

133. Finlay IG. Balanced policy in pain: evidence from the UK and India. J R Soc Med. 2013;106(12):470-3.

134. Cochella S, Bateman K. Providers’ role in the opioid epidemic: how we got here and how we move out. J Contin Educ Health Prof. 2016;36(Suppl 1):S26-7.

135. Max MB. The pain-free hospital: a goal whose time has come. Clin J Pain. 1990;6(4):306-10.

136. Art Van Zee. The promotion and marketing of OxyContin: commercial triumph, public health tragedy. Am J Public Health. 2009;99(2):221-7.

137. Manchikanti L, Helm S, Fellows B, et al. Opioid epidemic in the United States. Pain Physician. 2012;15(3 Suppl):ES9-38.

138. Fauber J. Patient satisfaction scores and the link to opioid prescribing. J Am Med Assoc. 2012;307(18):1901-2.

139. Daubresse M, Chang HY, Yu Y, et al. Trends in opioid analgesic prescribing in United States outpatient settings, 2OO6-20lO. Med Care. 2013;51(10):934-40.

140. Fischer B, Keates A, Cassadonte P, et al. High-volume opioid prescribing: a cross-national study of North America. Drug Alcohol Rev. 2014;33(3):213-20.

141. Hadland SE, Rivera-Aguirre A, Marshall BDL, et al. Association of pharmaceutical industry marketing of opioid products with mortality from opioid overdoses. JAMA Netw Open. 2019;2(1):e187009.

142. Volkow ND, McLellan AT. Opioid abuse in chronic pain— misconceptions and mitigation strategies. N Engl J Med. 2016;374(13):1253-63.

143. Webster LR, Webster RM. Predictors of accidental opioid overdose: a retrospective study. Pain Med. 2011;12(Suppl 2):S86-96.

144. Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374(2):154-63.

145. Mars SG, Rosenblum D, Ciccarone D. Illicit fentanyl in the 21st century heroin market: a rapid ethnography. J Psychoactive Drugs. 2019;51(2):121-30.

146. Armenian P, Vo KT, Barr-Walker J, et al. Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology. 2018;134(Pt A):121-32.

147. Ciccarone D. The triple wave of opioid overdose deaths in the United States. Am J Public Health. 2019;109(1):77-81.

148. Dasgupta N, Beletsky L, Ciccarone D. Beyond the opioid crisis: a holistic view of health outcomes. Am J Public Health. 2018;108(2):182- 6.

149. Preston MA, Moore SR. Life expectancy and the opioid crisis: a regional analysis. Health Aff (Millwood). 2019;38(7):1122-8.

150. Florence CS, Luo F, Rice K. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2021;218:108350.

151. Zin CS, Chen LC, Knaggs RD. Prescribing of strong opioids in Europe: a regional report. Eur J Pain. 2014;18(6):822-8.

152. Giraudon I, Hedrich D, Mounteney J, et al. Are we seeing an increase in opioid-related harms in Europe? Int J Drug Policy. 2016;30:1-4.

153. Muller-Schwefe G, Uberall MA. Opioid prescribing for chronic non-cancer pain in Germany: a retrospective database analysis. Curr Med Res Opin. 2015;31(9):1733-41.

154. Hauser W, Schug S, Furlan AD. The opioid epidemic and the role of the Nordic states. Acta Anaesthesiol Scand. 2017;61(10):1240-52.

155. van Amsterdam J, van den Brink W. The misuse of prescription opioids: a European perspective. Lancet Psychiatry. 2015;2(1):38-40.

156. EMCDDA. Drug-related deaths and mortality in Europe: 2021 report. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2021.

157. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;(1):CD006605.

158. Fischer B, Rehm J, Tyndall M. Preventing opioid-related harms: what we can learn from the North American crisis. J Public Health (Oxf). 2016;38(4):659-62.

159. Hedrich D, Pirona A, Wiessing L. From science to policy: harm reduction in the European context. Int J Drug Policy. 2018;56:201-10.

160. Gisev N, Larance B, Degenhardt L. The role of opioid substitution therapy in preventing opioid-related mortality. Expert Rev Neurother. 2015;15(11):1241-3.

161. Kalso E. Opioids in chronic non-cancer pain: European clinical guidelines. Eur J Pain. 2005;9(2):131-5.

162. Griffith JD. Pharmaceutical gatekeeping and opioid safety in primary care. Eur J Gen Pract. 2018;24(1):44-50.

163. Seyler T, Giraudtiere L. Comparative opioid regulation: US vs Europe. Pharmacoepidemiol Drug Saf. 2014;23(S1):45-6.

164. Campbell CI, Weisner C, LeResche L, et al. Trends in opioid use: the American market-driven experience. Health Aff (Millwood). 2010;29(12):2135-41.

165. Strang J, McDonald R, Alqurshi A, et al. Naloxone without prescription: less-cited barriers in Europe. Lancet. 2014;383(9912):188- 9.

166. Paice JA. Global access to pain relief: the paradox of opioid availability. JAMA Oncol. 2016;2(11):1405-6.

167. Scholten W, Henningfield JE. Balanced opioid policies: the human rights imperative. J Law Med Ethics. 2016;44(3):471-8.

168. Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N Engl J Med. 2017;377(4):391-4.

169. De Luca MA, Malatynska E, Fattore L. Preclinical development of safer analgesics: biased vs partial agonism. MDPI Molecules.

2020;25(17):3870.

170. Saloner B, McGinty EE. A public health strategy for the opioid crisis. Public Health Rep. 2018;133(1_suppl):24S-34S.

171. Kishore SP, Siegel K. Global pain management: a pharmacologic and policy imperative. Glob Heart. 2012;7(3):255-60.

172. D’Arcy Y. The evolution of pain management: how the pendulum swung. J Nurs Reg. 2011;2(1):4-10.

173. Berry PH. The role of accreditation in pain management: history and future. J Opioid Manag. 2006;2(5):253-7.

174. Kesselheim AS, Avorn J. The role of FDA in the opioid epidemic: a retrospective analysis. Health Aff (Millwood). 2020;39(3):432-40.

175. Hollmann D. The impact of institutional incentives on opioid prescribing. Surg Neurol Int. 2016;7(Suppl 25):S664-8.

176. Chen JH, Hom J, Richman I, et al. The unintended consequences of patient satisfaction scores on opioid prescribing. J Gen Intern Med. 2014;29(Suppl 1):S123.

177. Manchikanti L, Helm S, Fellows B, et al. Opioid epidemic in the United States. Pain Physician. 2012;15(3 Suppl):ES9-38.

178. Fischer B, Keates A, Cassadonte P, et al. High-volume opioid prescribing: a cross-national study of North America. Drug Alcohol Rev. 2014;33(3):213-20.

179. Hadland SE, Rivera-Aguirre A, Marshall BDL, et al. Association of pharmaceutical industry marketing of opioid products with mortality from opioid overdoses. JAMA Netw Open. 2019;2(1):e187009.

180. Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of opioids. In: Anesthetic Pharmacology. 2nd ed. Cambridge: Cambridge University Press; 2011. p. 531-56.

181. Webster LR, Webster RM. Predictors of accidental opioid overdose: a retrospective study. Pain Med. 2011;12(Suppl 2):S86-96.

182. Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374(2):154-63.

183. Mars SG, Rosenblum D, Ciccarone D. Illicit fentanyl in the 21st century heroin market: a rapid ethnography. J Psychoactive Drugs. 2019;51(2):121-30.

184. Armenian P, Vo KT, Barr-Walker J, et al. Fentanyl, fentanyl analogs and novel synthetic opioids: a comprehensive review. Neuropharmacology. 2018;134(Pt A):121-32.

185. Ciccarone D. The triple wave of opioid overdose deaths in the United States. Am J Public Health. 2019;109(1):77-81.

186. Dasgupta N, Beletsky L, Ciccarone D. Beyond the opioid crisis: a holistic view of health outcomes. Am J Public Health. 2018;108(2):182- 6.

187. Preston MA, Moore SR. Life expectancy and the opioid crisis: a regional analysis. Health Aff (Millwood). 2019;38(7):1122-8.

188. Florence CS, Luo F, Rice K. The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2021;218:108350.

189. Zin CS, Chen LC, Knaggs RD. Prescribing of strong opioids in Europe: a regional report. Eur J Pain. 2014;18(6):822-8.

190. Giraudon I, Hedrich D, Mounteney J, et al. Are we seeing an increase in opioid-related harms in Europe? Int J Drug Policy. 2016;30:1-4.

191. Muller-Schwefe G, Uberall MA. Opioid prescribing for chronic non-cancer pain in Germany: a retrospective database analysis. Curr Med Res Opin. 2015;31(9):1733-41.

192. Hauser W, Schug S, Furlan AD. The opioid epidemic and the role of the Nordic states. Acta Anaesthesiol Scand. 2017;61(10):1240-52.

193. van Amsterdam J, van den Brink W. The misuse of prescription opioids: a European perspective. Lancet Psychiatry. 2015;2(1):38-40.

194. EMCDDA. Drug-related deaths and mortality in Europe: 2021 report. Lisbon: European Monitoring Centre for Drugs and Drug Addiction; 2021.

195. Noble M, Treadwell JR, Tregear SJ, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;(1):CD006605.

196. Fischer B, Rehm J, Tyndall M. Preventing opioid-related harms: what we can learn from the North American crisis. J Public Health (Oxf). 2016;38(4):659-62.

197. Hedrich D, Pirona A, Wiessing L. From science to policy: harm reduction in the European context. Int J Drug Policy. 2018;56:201-10.

198. Gisev N, Larance B, Degenhardt L. The role of opioid substitution therapy in preventing opioid-related mortality. Expert Rev Neurother. 2015;15(11):1241-3.

199. Kalso E. Opioids in chronic non-cancer pain: European clinical guidelines. Eur J Pain. 2005;9(2):131-5.

200. Griffith JD. Pharmaceutical gatekeeping and opioid safety in primary care. Eur J Gen Pract. 2018;24(1):44-50.

201. Seyler T, Giraudtiere L. Comparative opioid regulation: US vs Europe. Pharmacoepidemiol Drug Saf. 2014;23(S1):45-6.

202. Campbell CI, Weisner C, LeResche L, et al. Trends in opioid use: the American market-driven experience. Health Aff (Millwood). 2010;29(12):2135-41.

203. Strang J, McDonald R, Alqurshi A, et al. Naloxone without prescription: less-cited barriers in Europe. Lancet. 2014;383(9912):188- 9.

204. Paice JA. Global access to pain relief: the paradox of opioid availability. JAMA Oncol. 2016;2(11):1405-6.

205. Scholten W, Henningfield JE. Balanced opioid policies: the human rights imperative. J Law Med Ethics. 2016;44(3):471-8.

206. Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N Engl J Med. 2017;377(4):391-4.

207. De Luca MA, Malatynska E, Fattore L. Preclinical development of safer analgesics: biased vs partial agonism. MDPI Molecules.

2020;25(17):3870.

208. Saloner B, McGinty EE. A public health strategy for the opioid crisis. Public Health Rep. 2018;133(1_suppl):24S-34S.

209. Kishore SP, Siegel K. Global pain management: a pharmacologic and policy imperative. Glob Heart. 2012;7(3):255-60.

210. Bayer R, Ghodse H. Drug control: history, policy, and management. Oxford: Oxford University Press; 1999.

211. Bewley-Taylor DR. The United Nations and drug control: shaping the modern regime. New York: Routledge; 2012.

212. Jelsma M. The UN drug control conventions: a primer. Amsterdam: Transnational Institute; 2015.

213. Lohman D. The impact of the 1961 Single Convention on global pain management. J Law Med Ethics. 2012;40(2):188-202.

214. International Narcotics Control Board. Report of the INCB for 2015: availability of internationally controlled medicines. Vienna: United Nations; 2016.

215. Scholten W, Christensen AE. Excessive control of medicines: a

violation of the right to health. Health Hum Rights. 2017;19(1):131-46.

216. Hallam C. The International Narcotics Control Board: watchman or guardian? London: International Drug Policy Consortium; 2014.

217. Costa AJ. The INCB and the monitoring of opioid consumption data. Drug Test Anal. 2011;3(7-8):445-51.

218. Ghodse H, Hallam C. The INCB’s evolving role in pain relief access. Int Drug Policy J. 2010;21(3):212-5.

219. Lines R. The International Narcotics Control Board and the death penalty. In: Drug control and human rights in international law. Cambridge: Cambridge University Press; 2017. p. 142-82.

220. Giraudon I, Hedrich D. Regulatory signaling and its impact on medical opioid use. Pharmaceut Med. 2016;30(4):189-94.

221. Laing R. The WHO Model List of Essential Medicines: a 40-year perspective. Bull World Health Organ. 2017;95(12):847-8.

222. Peretti-Watel P. Essential medicines for pain: a comparative study of the EML. Soc Sci Med. 2012;75(4):612-9.

223. Magrini N, Robertson J. Normative guidance and the WHO EML. Lancet. 2015;385(9975):1284-5.

224. Hogerzeil HV. The right to essential medicines. Lancet. 2006;367(9508):405-11.

225. Wiffen PJ, Derry S. Inclusion of morphine on the EML and its effect on national policy. Cochrane Database Syst Rev.

2017;(7):ED000122.

226. Cherny NI. The disparity between normative standards and patient access in LMICs. Ann Oncol. 2013;24(Suppl 11):xi13-8.

227. World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Geneva: WHO Press; 2018.

228. Stjernsward J. The WHO analgesic ladder: its development and impact. Pain Manag Nurs. 2002;3(1):15-20.

229. Vijayan R. The role of healthcare provider education in opioid safety. Singapore Med J. 2011;52(3):141-5.

230. Burci GL. The legal status of WHO non-binding guidance. In: Research handbook on global health law. Cheltenham: Edward Elgar Publishing; 2018. p. 45-68.

231. European Medicines Agency. The EMA’s role in regulating controlled substances. Amsterdam: EMA Press; 2019.

232. Gilsenan A. Pharmacovigilance of opioid medicines in the European Union. Drug Saf. 2016;39(11):1055-68.

233. Jaroslawski S. National competence and the regulation of opioid prescribing in Europe. Eur J Health Law. 2015;22(4):351-70.

234. EMCDDA. Pharmacovigilance and drug misuse: the EMA- EMCDDA cooperation. Lisbon: EMCDDA; 2018.

235. Waller P. Risk management plans for opioids: a regulatory perspective. Pharmacoepidemiol Drug Saf. 2014;23(4):331-8.

236. van Amsterdam J. Fragmented opioid policy in the EU: a risk assessment. Lancet Psychiatry. 2015;2(1):38-40.

237. Zin CS. Heterogeneous opioid use in Europe: the role of national culture. Eur J Pain. 2014;18(6):822-8.

238. Griggs CA. National monitoring systems: PDMPs as a regulatory tool. J Med Regul. 2015;101(2):18-24.

239. Haegerich TM. The impact of PDMPs on high-risk opioid prescribing. Health Aff (Millwood). 2014;33(7):1194-203.

240. Cleary J. Regulatory instruments as barriers in low-resource settings. J Palliat Care. 2015;31(2):112-8.

241. Smith T. The influence of health system incentives on opioid use. J Health Econ. 2016;45:121-35.

242. Seyler T. Reimbursement barriers for non-opioid pain therapies. Eur J Health Econ. 2018;19(3):415-28.

243. Scholten W. Aligning opioid control with health system design. Drugs Health Serv Res. 2021;1:100004.

244. Brennan F. The persistent tension: access vs control in pain relief. Am J Public Health. 2019;109(1):61-5.

245. Lohman D. Regulatory tension in the global opioid regime. Health Hum Rights. 2010;12(2):109-22.

246. Scholten W. Two parallel crises: untreated pain and overdose. J Law Med Ethics. 2016;44(3):471-8.

247. Kishore SP. Balanced regulatory frameworks: a global health imperative. Glob Heart. 2012;7(3):255-60.

248. Smith T. Pharmaceutical science and the regulatory environment. Pharm Res. 2016;33(10):2341-5.

249. Griffith JD. The role of pharmacology in designing drug controls. J Med Ethics. 2012;38(1):15-20.

250. Paice JA. Bridging the gap: science, policy, and the opioid paradox. JAMA Oncol. 2016;2(11):1405-6.

251. Barbosa J, Oliveira-Ferreira J. Pharmacology and toxicology of opioids—recent advances and new perspectives. Pharmaceuticals (Basel). 2025;18(7):1055.

252. Kelly E. A biased view of p-opioid receptors? Mol Pharmacol.

2013;84(1):153-61.

253. Kruegel AC, Varadi A. Emerging opioids: biased signaling and atypical mechanisms of action. Neuropharmacology. 2018;134(Pt A):121-32.

254. Webster L, Karan S. Buprenorphine: unique partial agonism and the ceiling effect on respiratory depression. J Pain Res. 2020;13:2567- 79.

255. Gholap A, Pardeshi S. Buprenorphine pharmacokinetics in opioid use disorder: a review of current clinical evidence. ResearchGate.

2020; [DOI: 10.13140/RG.2.2.34532.2590].

256. Kumar S, Walia A. Impact of abuse-deterrent formulations of opioids in patients with chronic pain: a cost-effectiveness analysis. ICER Consensus Report. 2019.

257. DiPrete BL, Dasgupta N. Abuse-deterrent formulations and opioid-related harms in North Carolina, 2010-2018. Am J Epidemiol. 2025;194(3):680-90.

258. Cicero TJ, Ellis MS. Abuse-deterrent formulations and the "balloon effect": shifting patterns of misuse. J Pain. 2015;16(10):962-8.

259. Scholten W, Christensen AE. Excessive control of medicines in LMICs: a violation of the right to health. Health Hum Rights. 2017;19(1):131-46.

260. Kasto J, Castle J. A non-opioid multimodal pain protocol achieves equivalent pain control after total shoulder arthroplasty: a randomized-controlled trial. JSES Int. 2024;8(6):1369.

261. Mao J. The role of adjunctive analgesics in opioid-sparing protocols. Anesthesiol Clin. 2017;35(2):223-31.

262. Magrini N, Robertson J. Normative guidance and the WHO Essential Medicines List: a 40-year perspective. Lancet. 2015;385(9975):1284-5.

263. Lohman D. Balanced opioid policy: the impact of the UK and India experiences. J R Soc Med. 2013;106(12):470-3.

264. Rajagopal MR. The Kerala model: overcoming regulatory barriers to palliative care in India. Indian J Palliat Care. 2015;21(1):15-21.

265. Hollmann D. The impact of institutional incentives on balanced opioid prescribing. Surg Neurol Int. 2016;7(Suppl 25):S664-8.

266. Costa AJ. The INCB and the monitoring of opioid consumption data. Drug Test Anal. 2011;3(7-8):445-51.

267. Kishore SP, Siegel K. Global pain management: a pharmacologic and policy imperative. Glob Heart. 2012;7(3):255-60.

268. Vijayan R. The role of healthcare provider education in opioid safety and access. Singapore Med J. 2011;52(3):141-5.

269. Jelsma M. Civil-society driven drug policy reform for health and human welfare: India. Transnatl Inst. 2017; [ID: 312055566].

270. Cherny NI. The disparity between normative standards and patient access in LMICs. Ann Oncol. 2013;24(Suppl 11):xi13-8.

271. National Academies of Sciences, Engineering, and Medicine. Integrating harm reduction into medical care: lessons from three models. NCBI Bookshelf. 2020.

272. Reason Foundation. Harm reduction: an evidence-based approach to the drug war. Policy Briefing. 2025; [ID: 5.2].

273. Gisev N, Larance B. The role of opioid substitution therapy in preventing opioid-related mortality. Expert Rev Neurother. 2015;15(11):1241-3.

274. Seyler T, Vicini R. Integrating pharmacology into regulatory science: a cross-national study. Eur J Gen Pract. 2018;24(1):44-50.

275. Griffith JD. The role of pharmacology in designing drug controls. J Med Ethics. 2012;38(1):15-20.

276. Smith T. Pharmaceutical science and the regulatory environment. Pharm Res. 2016;33(10):2341-5.

277. Paice JA. Global access to pain relief: bridging the gap between science and policy. JAMA Oncol. 2016;2(11):1405-6.

278. Knaul FM, Farmer PE. Alleviating the access abyss in palliative care and pain relief. Lancet. 2018;391(10128):1391-454.

279. Harding R, Gwyther L. Community engagement and the reduction of opioid stigma. Lancet. 2013;381(9874):1251-3.

280. Vijayan R. Developing home care and oral morphine programs in resource-limited settings. Indian J Palliat Care. 2015;21(1):15-21.

281. NACHC. Increasing equity in pain management, substance use disorder treatment, and linkages to care. Health Center Resource Guide. 2024.

282. Volkow ND, Collins FS. The role of science in addressing the opioid crisis. N Engl J Med. 2017;377(4):391-4.

283. Slaunwhite A, Min JE. Effect of risk mitigation guidance on mortality during dual public health emergencies. BMJ. 2024;384:e076336.

284. Caudle KE, Dunnenberger HM. Reviewing pharmacogenetics to advance precision medicine for opioids. ResearchGate. 2025; [ID: 354541700].

285. Seyler T, Vicini R. The pharmacological deterministic model of drug policy: a critical review. Pharmaceut Med. 2018;32(2):89-95.

286. Barbosa J, Oliveira-Ferreira J. High-potency opioids and the narrow therapeutic index: a population-level risk assessment. Pharmaceuticals (Basel). 2025;18(7):1055.

287. Meldrum ML. The pharmacist’s role in the "pain as the fifth vital sign" movement: a historical cautionary tale. J Am Pharm Assoc. 2016;56(5):493-5.

288. Vargas-Schaffer G, Cogan J. Opiophobia and the pharmacological justification for restriction in LMICs. Front Pharmacol. 2016;7:42.

289. Joshi S. The impact of limited toxicological monitoring on opioid availability in rural India. J Palliat Care. 2020;35(3):141-5.

290. Scholten W. Pharmacology as policy: how drug properties influence regulatory signaling. Drugs Health Serv Res. 2021;1:100004.

291. Cherny NI. The global opioid paradox: an analysis of systemic health inequity. Ann Oncol. 2013;24(Suppl 11):xi13-8.

292. Brennan F, Lohman D. The right to pain relief as a human right: an ethical and legal framework. Am J Public Health. 2019;109(1):61-5.

293. Dasgupta N, Beletsky L. Social determinants of the opioid crisis in marginalized North American communities. Am J Public Health. 2018;108(2):182-6.

294. Mwangi-Powell FN. Palliative care and the end-of-life pain gap in Sub-Saharan Africa. Ecancermedicalscience. 2011;5:208.

295. Paice JA. The failure of translation: from pharmacological discovery to equitable care. JAMA Oncol. 2016;2(11):1405-6.

296. Giraudon I, Hedrich D. Mediating molecules: how regulatory frameworks filter pharmacological effects. Int J Drug Policy. 2016;30:1- 4.

297. Bewley-Taylor DR. Prohibition vs. care: the historical evolution of the UN drug control treaties. New York: Routledge; 2012.

298. Maurina T. Conservative treaty interpretation and its impact on Southeast Asian health systems. Int J Drug Policy. 2013;24(6):546-51.

299. Hollmann D. Fragmented oversight and the normalization of high-volume opioid prescribing. Surg Neurol Int. 2016;7(Suppl 25):S664-8.

300. Kishore SP, Siegel K. Proportionality in drug governance: balancing the risks of over- and under-regulation. Glob Heart. 2012;7(3):255-60.

301. Groom J. The legal obligation to provide pain relief: a critique of the 1961 Single Convention. J Int Drug Policy Rev. 2019;12(4):33-45.

302. Maurina T. Technical assistance for narcotic regulation: bridging the gap in LMIC administrative capacity. Int J Drug Policy.

2013;24(6):546-51.

303. Hallam C. The INCB and the facilitation of medical access: a roadmap for reform. London: International Drug Policy Consortium; 2014.

304. Kishore SP, Siegel K. Proportionality in medicine governance: adapting drug controls to local health system capacity. Glob Heart. 2012;7(3):255-60.

305. Rajagopal MR. Simplifying the procurement of oral morphine: lessons from the Kerala experience. Indian J Palliat Care. 2015;21(1):15-21.

306. Campbell CI, Weisner C. Moving beyond punitive regulation: a health-first approach to the North American opioid crisis. Health Aff (Millwood). 2010;29(12):2135-41.

307. Knaul FM, Farmer PE. Alleviating the access abyss: integrating palliative care into universal health coverage. Lancet.

2018;391(10128):1391-454.

308. Seyler T. The role of reimbursement policy in shaping multimodal pain management. Eur J Health Econ. 2018;19(3):415-28.

309. Brennan F, Lohman D. Untreated pain as a violation of the right to health: an international legal perspective. Am J Public Health. 2019;109(1):61-5.

310. Azzam AA, McDonald J. Biased ligands and the future of safe analgesia: a pharmacological review. Br J Anaesth. 2019;122(6):e136- 45.

311. Smith T. Formulation design for resource-limited settings: stability and safety of oral morphine preparations. Pharm Res. 2016;33(10):2341-5.

312. Waller P. Real-world evidence and adaptive regulation in the opioid market. Pharmacoepidemiol Drug Saf. 2014;23(4):331-8.

313. Griffith JD. Pharmaceutical transparency and the ethical duty to report addiction risk in early-phase trials. J Med Ethics. 2012;38(1):15- 20.

314. Mwangi-Powell FN. Strengthening health systems through the integration of pain management. Ecancermedicalscience. 2011;5:208.

315. Harding R, Gwyther L. Combating opiophobia: community engagement strategies in palliative care. Lancet. 2013;381(9874):1251- 3.

316. Logie CH, Williams DJ. The data gap: challenges in measuring opioid consumption in low-income settings. Glob Health Action. 2015;8:26543.

317. Scholten W. Interdisciplinary collaboration as a catalyst for resolving the global opioid paradox. Drugs Health Serv Res. 2021;1:100004.

[...]

• Hochschule: University of Wales, Newport, (Newport University)
• Veranstaltung: Ph.D. in Pharmaceutical Science
• Note: A-
• Autor: Vincent Weiss (Autor:in)
• Erscheinungsjahr: 2026
• Seiten: 84
• Katalognummer: V1733273
• ISBN (PDF): 9783389197240
• ISBN (Buch): 9783389197257
• Sprache: Englisch
• Schlagworte: The Global Opioid Paradox, Single Convention on Narcotic Drugs (1961), International Narcotics Control Board (INCB), Controlled Substances Act (CSA), Opiophobia, The Fifth Vital Sign, Palliative Care, Essential Medicines List (EML), Iatrogenic Addiction